STAT3 phosphorylation and transcriptional activity promotes breast cancer growth and metastasis. We have previously reported that the transcriptional adaptor LMO2 is required for metastasis in breast cancer and promotes STAT3-JAK2 interaction, leading to STAT3 phosphorylation in metastasis-initiating cells. Here, we find that constitutively activated STAT3 is insufficient to drive metastasis in the absence of LMO2. Mechanistically, we find that LMO2 is required not only for STAT3 phosphorylation in the cytoplasm but also for STAT3 translocation to the nucleus. These data suggest that LMO2 promotes STAT3 activation and localization to the nucleus in breast cancer cells.
","acknowledgements":"We thank Benjamin Abrams, UCSC Life Sciences Microscopy Center, RRID: SCR_021135 for technical support during image acquisition and processing.
","authors":[{"affiliations":["University of California, Santa Cruz","University of California, Santa Cruz"],"departments":["Molecular, Cell & Developmental Biology","Institute for the Biology of Stem Cells"],"credit":["dataCuration","investigation","methodology","visualization","writing_originalDraft","formalAnalysis","conceptualization"],"email":"ifetter@ucsc.edu","firstName":"Isobel J","lastName":"Fetter","submittingAuthor":false,"correspondingAuthor":false,"equalContribution":false,"WBId":null,"orcid":null},{"affiliations":["University of California, Santa Cruz"],"departments":["Molecular, Cell & Developmental Biology"],"credit":["dataCuration","investigation","methodology"],"email":"vharoaco@ucsc.edu","firstName":"Veronica","lastName":"Haro Acosta","submittingAuthor":false,"correspondingAuthor":false,"equalContribution":false,"WBId":null,"orcid":null},{"affiliations":["University of California, Santa Cruz"],"departments":["Molecular, Cell & Developmental Biology"],"credit":["investigation","methodology"],"email":"sparecadan@gmail.com","firstName":"Sachin ","lastName":"Parecadan","submittingAuthor":false,"correspondingAuthor":false,"equalContribution":false,"WBId":null,"orcid":null},{"affiliations":["University of California, Santa Cruz","University of California, Santa Cruz","University of California, Santa Cruz"],"departments":["Molecular, Cell & Developmental Biology","Institute for the Biology of Stem Cells","Genomics Institute",""],"credit":["conceptualization","formalAnalysis","fundingAcquisition","investigation","project","supervision","writing_originalDraft"],"email":"ssikanda@ucsc.edu","firstName":"Shaheen S","lastName":"Sikandar","submittingAuthor":true,"correspondingAuthor":true,"equalContribution":false,"WBId":null,"orcid":null}],"awards":[{"awardId":" R37CA269754","funderName":"National Cancer Institute (United States)","awardRecipient":"Shaheen Sikandar"},{"awardId":"5T32GM133391","funderName":"National Institutes of Health (United States)","awardRecipient":"Isobel Fetter"},{"awardId":"EDUC4-12759","funderName":"California Institute for Regenerative Medicine (United States)","awardRecipient":"Isobel Fetter"}],"conflictsOfInterest":null,"dataTable":null,"extendedData":[],"funding":"","image":{"url":"https://portal.micropublication.org/uploads/023787aedbfaa508ec1d0d56214b7577.png"},"imageCaption":"Figure Legend: (A) Schematic of aSTAT3 and shLMO2 expression in MDA-MB-468 cells followed by orthotopic transplant in NSG mice to evaluate tumor burden and metastasis. (B) Immunoblotting of MDA-MB-468 cells transduced with either control (pSicoR) or constitutively active STAT3 plasmid. (C) Tumor weight in control (pRSI12/pSicoR), shLMO2 (shLMO2/pSicoR), aSTAT3 (pRSI12/aSTAT3), and shLMO2/aSTAT3 tumors generated from MDA-MB-468 cell xenografts (n = 5 mice per group). (D) Representative fluorescent images of spontaneous RFP+/GFP+ lung metastases from mice with control, shLMO2, aSTAT3, and shLMO2/aSTAT3 tumors in (B). (E) Quantification of metastases in (D). Data shown as mean ± standard deviation. (F) Representative immunoblot of phosphorylated STAT3 in the cytoplasm and nucleus of MDA-MB-468 cells transduced with control (pRSI12/pSicoR), shLMO2 (shLMO2/pSicoR), aSTAT3 (pRSI12/aSTAT3), and shLMO2/aSTAT3. (G) Quantification of phosphorylated STAT3 in (F), n = 3 biological replicates. Statistical significance was calculated with ordinary 1-way ANOVA with multiple comparisons (C, E) and multiple unpaired t-tests (G). * P < 0.05, ** P < 0.01, *** P < 0.001. (A) Created with Biorender.com
","imageTitle":"LMO2 regulates STAT3 localization to the nucleus in breast cancer cells
","methods":"Cell Line Generation
MDA-MB-468 and HEK293T cells were obtained from the American Type Culture Collection. Cells were cultured in DMEM supplemented with penicillin (120 ug/mL), streptomycin (100 ug/mL), amphotericin B (0.25 ug/mL), and 10% FBS. LMO2 shRNA targeting the 3′UTR (5′-GACGCATTTCGGTTGAGAA-3′) was cloned into the pRSI12-U6-(sh)-HTS4-UbiC-TagRFP-2A-Puro shRNA expression vector (Cellecta). The pRSI12 empty vector was used as a control. EF.STAT3C.Ubc.GFP was a gift from Linzhao Cheng (Addgene plasmid #24983; http://n2t.net/addgene:24983; RRID: Addgene_24983). pSicoR was a gift from Tyler Jacks (Addgene plasmid #11579; http://n2t.net/addgene:11579; RRID: Addgene_11579) and was used as an empty vector control for the aSTAT3 plasmid. Viruses were produced in HEK293T cells using the second-generation lentiviral system and transfection using Lipofectamine 2000 (Life Technologies). Supernatants were collected at 48 and 72 hours, filtered with a 0.45-μm filter, and precipitated with lentivirus precipitation solution (Alstem LLC) per the manufacturer’s instructions. Viral titers were determined by flow cytometry analyses of HEK293T cells infected with serial dilutions of concentrated virus.
Mouse Models
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) (stock #005557) mice were purchased from The Jackson Laboratory and bred at the University of California Santa Cruz (UCSC). All mice used for this study were maintained at the UCSC Animal Facility in accordance with the guidelines set forth by UCSC and the Institutional Animal Care and Use Committee (Protocol number SIKAS2010).
Xenografts
To prepare cells for orthotopic injection, cells were trypsinized with standard protocols, and live cell counts were assessed by Trypan Blue staining. Each cell line was resuspended in DMEM containing 40% Matrigel and subcutaneously injected into the fourth abdominal fat pads on one side of female NSG mice. 100,000 cells were used for each injection. Mice were monitored every week for tumor growth. All mice were euthanized if tumor growth reached the endpoint (1500 mm3). Tumor size was measured using digital calipers. Tumors were harvested and weighed and the number of GFP/RFP double-positive lung metastases was counted using the ImageJ software.
Subcellular fractionation
Whole cell lysates were generated by lysis with radioimmunoprecipitation assay (RIPA) buffer, along with protease and phosphatase inhibitor cocktails (Thermo Fisher Scientific). Subcellular fraction was performed as described previously (Baghirova et al., 2015; Rubio et al., 2024). Briefly, cultured cells were washed with room temperature PBS before detachment with trypsin. Cells were resuspended in DMEM with 10% FBS and pelleted at 500 x g. Increasingly strong detergents were used to lyse the cells, and the cytoplasmic fraction, the membrane-bound organelle fraction, and finally the nuclear fraction were collected from the supernatant. After the supernatant was collected for each fraction, the remaining cell material was washed 3 times with the respective lysis buffer to remove any remaining protein before the next lysis step. 40 μL of each sample was added to 10 μL 4x NuPAGE LDS buffer with 4% β-mercaptoethanol, then boiled at 95°C for 5 minutes before gel electrophoresis.
Western Blotting
SDS-PAGE gels were run at 100 V for 70 min, then transferred onto polyvinylidene difluoride membranes (#IPFL00010, Millipore, Billerica, MA) at 70 V for 90 min. Membranes were blocked with 5% BSA/tris-buffered saline–Tween 0.1% (TBST) for 1 hour at RT and then subsequently probed with primary antibodies diluted at 1:1000 in 5% BSA/tris-buffered saline–Tween 0.1% (TBST) overnight at 4°C. Membranes were then incubated in secondary antibodies containing HRP for 1 hour at RT. Luminol detection reagents were used to enable visualization on the Biorad ChemiDoc. Washes in between incubations were done for 10 min × 3 using TBST. Western blot bands were quantified using ImageJ software and normalized to the total amount of STAT3.
Statistical Analysis
All graphs show the mean, and error bars indicate standard deviations. P values are calculated using ANOVA or multiple t-tests, as indicated in the figure legend. All P values were calculated using GraphPad Prism. For animal studies, sample size was not predetermined to ensure adequate power to detect a prespecified effect size, no animals were excluded from analyses, and investigators were not blinded to group allocation during experiments.
","reagents":"Cell Line | Genotype | Available From |
MDA-MB-468 | Homo sapiens, isolated from a pleural effusion of a female patient with metastatic adenocarcinoma of the breast | ATCC |
HEK293T | Homo sapiens, derived from embryonic kidney 293 cells, contains SV40 T-antigen | ATCC |
Plasmid | Description |
pSicoR | pSicoR was a gift from Tyler Jacks (Addgene plasmid #11579; http://n2t.net/addgene:11579; RRID: Addgene_11579) |
aSTAT3 | EF.STAT3C.Ubc.GFP was a gift from Linzhao Cheng (Addgene plasmid #24983; http://n2t.net/addgene:24983; RRID: Addgene_24983) |
pRSI12 | pRSI12-U6-(sh)-HTS4-UbiC-TagRFP-2A-Puro shRNA expression vector (Cellecta) |
shLMO2 | LMO2 shRNA targeting the 3′UTR (5′-GACGCATTTCGGTTGAGAA-3′) was cloned into the pRSI12 shRNA expression vector (Cellecta) |
Animal Strain | Genotype | Available From |
NSG Mus musculus | NOD.Cg-PrkdcscidIl2rgtm1Wjl/Szj | Jackson Laboratory (stock #005557) |
Antibody | Animal and Clonality | Immunogen | Concentration |
anti-FLAG | Mouse monoclonal, clone M2 (Sigma-Aldrich #F1804) | DYKDDDDK | 1:1000 |
anti-STAT3 | Mouse monoclonal, clone 9D8 (Abcam #ab119352) | peptide within human STAT3 aa 650 to the C-terminus | 1:1000 |
anti-pSTAT3 (Y705) | Rabbit monoclonal, clone D3A7 (Cell Signaling Technology #9145) | synthetic phosphopeptide corresponding to residues surrounding Tyr705 of mouse Stat3 | 1:1000 |
anti-Lamin B | Goat polyclonal (Santa Cruz Biotechnology #sc-6216) | peptide mapping at the C-terminus of human Lamin B1 | 1:1000 |
anti-β-Actin, HRP conjugated | Mouse monoclonal, clone BA3R (Invitrogen #MA5-15739-HRP) | β-actin N-terminal peptide | 1:5000 |
anti-mouse IgG, HRP conjugated | Horse polyclonal (Cell Signaling Technology #7076) | mouse IgG heavy and light chain | 1:5000 |
anti-rabbit IgG, HRP conjugated | Goat polyclonal (Cell Signaling Technology #7074) | rabbit IgG heavy and light chain | 1:5000 |
anti-goat IgG, HRP conjugated | Donkey polyclonal (Jackson ImmunoResearch #705-035-147) | goat IgG heavy and light chain | 1:5000 |
Metastasis is the leading cause of breast cancer-related deaths, making it imperative to develop strategies to target metastasis (Dillekås et al., 2019; Siegel et al., 2025). It is well established that breast tumors contain heterogeneous populations, with only a small subset of tumor cells exhibiting tumor-initiating and metastatic capacity (Lawson et al., 2015; Celià-Terrassa and Kang, 2016; Sikandar et al., 2017). Understanding molecular mechanisms regulating metastasis-initiating cells (MICs) will broaden potential targets and treatment strategies for breast cancer.
Previous studies have demonstrated that inflammatory cytokines such as IL6 and TNFɑ activate the JAK/STAT and NFκB pathways, resulting in transcriptional changes leading to tumorigenesis and metastasis (Coussens and Werb, 2002; Quail and Joyce, 2013; Hibino et al., 2021). STAT3 is phosphorylated by JAK2, homodimerizes to move to the nucleus and regulate transcription of its target genes, promoting proliferation, survival, and self-renewal (Schindler and Jr, 1995).
We recently identified a population of MICs in breast cancer that express LMO2, a transcriptional adaptor protein in hematopoietic stem cells and a T-cell oncogene (Yamada et al., 1998; McCormack et al., 2010). Knocking down LMO2 did not affect the growth of primary tumors, but significantly reduced the number of circulating tumor cells and lung metastases (Sikandar et al., 2022). Mechanistically, we found that LMO2 binds to the transcription factor STAT3 and is required for STAT3 phosphorylation in breast cancer cells (Sikandar et al., 2022). Consistent with our previous findings, another study showed LMO2 activates STAT3 signaling in glioblastoma to increase cancer stemness, suggesting that LMO2 activates STAT3 signaling in multiple cancers (Park et al., 2022). Here, we further investigate interactions between LMO2 and STAT3 during breast cancer metastasis by combining constitutively activated STAT3 with the loss of LMO2.
STAT3 is constitutively activated in several cancers, including breast cancer (Kim et al., 2012; Carpenter and Lo, 2014; Galoczova et al., 2018; J.-H. Ma et al., 2020). Hence, we wanted to test whether activated STAT3 (aSTAT3) can rescue the effect of LMO2 knockdown. To test whether constitutively active STAT3 (aSTAT3) is sufficient to rescue the decreased metastatic potential observed upon LMO2 knockdown, we first obtained a FLAG-tagged aSTAT3 construct (Hillion et al., 2008) and confirmed its expression by immunoblotting (Fig. 1B). We then generated four cell lines combining LMO2 knockdown and aSTAT3 and their respective controls (Ventura et al., 2004). These cell lines were orthotopically transplanted into the mammary fat pad of female NSG mice, and tumor growth was monitored over time (Fig. 1A). We found that there is no difference in tumor growth between the control, shLMO2, aSTAT3, or aSTAT3/shLMO2 (Fig. 1C). This is consistent with our previous findings that LMO2 knockdown significantly reduced metastasis, but did not impact tumor growth (Sikandar et al., 2022). We also found that aSTAT3 did not increase the number of metastases (Fig. 1D-E). Importantly, mice with shLMO2/aSTAT3 tumors have reduced metastasis similar to the mice with LMO2 knockdown tumors, suggesting that the combination of constitutively active STAT3 and LMO2 knockdown is insufficient to rescue metastasis (Fig. 1D-E).
As LMO2 is an adaptor protein and facilitates the formation of transcription factor complexes (Yamada et al., 1998), we next wanted to understand whether LMO2 is required for STAT3 localization to the nucleus. Hence, we performed subcellular fractionation and immunoblotting to find that, as expected, pSTAT3 is primarily located in the nucleus in the control and aSTAT3 cell lines (Fig. 1E). However, in LMO2 knockdown cells, there is an equal distribution of pSTAT3 between the cytoplasm and the nucleus (Fig. 1E-F). This suggests that LMO2 is required for pSTAT3 localization to the nucleus in breast cancer cells. These data suggest a novel role for LMO2 in breast cancer cells. LMO2 not only helps stabilize JAK2-STAT3 interactions to promote phosphorylation, but it also continues to aid STAT3’s translocation to the nucleus.
STAT3 phosphorylation and nuclear localization are associated with tumorigenesis and metastasis in multiple cancers, with increased nuclear STAT3 leading to reduced overall survival in patients (Huang et al., 2017; Chen et al., 2023; Zhang et al., 2024). STAT3 can localize to the nucleus without phosphorylation, but phosphorylation is required for STAT3’s transcription factor activity (Liu et al., 2005). STAT3 is imported into the nucleus primarily through importin-ɑ3 (KPNA4) or importin-ɑ5 (KPNA1) in association with importin-β1 (KPNB1) (Liu et al., 2005; J. Ma and Cao, 2006). STAT3 is still found in the nucleus when LMO2 is knocked down, but nuclear pSTAT3 is significantly reduced (Fig. 1E-F). Structurally, LMO2 is composed of 2 LIM fingers, each containing 2 zinc finger motifs (El Omari et al., 2011). Interestingly, other zinc finger-containing proteins such as EZI (Nakayama et al., 2002), ZBP-89 (Wu et al., 2004), KLF4 (Qin et al., 2013), and IKZF1 and IKZF3 (Read et al., 2017) have been shown to associate with and modulate nuclear localization of STAT3.
STAT3 signaling is an appealing target for treating cancer. Multiple STAT3 inhibitors have been investigated in clinical trials with various efficacies and tolerances (Hong et al., 2013; Ogura et al., 2015; Oh et al., 2015; Jonker et al., 2016; Tolcher et al., 2018; Feldman, 2024), but there are currently no FDA-approved therapies targeting STAT3. Inhibiting STAT3 signaling can lead to off-target toxicity, so targeting STAT3 only in cancer cells could improve outcomes. Since the oncogenic effects depend on STAT3’s nuclear localization, disrupting its nuclear import represents an alternative therapeutic strategy. Disruption of LMO2-STAT3 interactions using newly developed inhibitors for LMO2 could prevent nuclear accumulation and suppress STAT3-driven transcription (Milton-Harris et al., 2020; Bery et al., 2021). Therapeutically, this approach offers a potential strategy to selectively target constitutively active STAT3 in tumors while sparing transient STAT3 activation in normal tissues. However, it is also possible that LMO2 has additional functions independent of its interaction with STAT3 that contribute to metastasis. Future structure-function studies will determine how LMO2 promotes STAT3 localization to the nucleus in metastasis-initiating cells and whether LMO2 binds to additional molecules to modulate metastasis in breast cancer.
","references":[{"reference":"Sikandar SS, Kuo AH, Kalisky T, Cai S, Zabala M, Hsieh RW, et al., Clarke MF. 2017. Role of epithelial to mesenchymal transition associated genes in mammary gland regeneration and breast tumorigenesis. Nature Communications. 8: 1669.","pubmedId":"","doi":"10.1038/s41467-017-01666-2"},{"reference":"Dillekas H, Rogers MS, Straume O. 2019. Are 90% of deaths from cancer caused by metastases?. Cancer Medicine. 8: 5574.","pubmedId":"","doi":"10.1002/cam4.2474"},{"reference":"Yamada Y, Warren AJ, Dobson C, Forster A, Pannell R, Rabbitts TH. 1998. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proceedings of the National Academy of Sciences. 95: 3890.","pubmedId":"","doi":"10.1073/pnas.95.7.3890"},{"reference":"Mc Cormack MP, Young LF, Vasudevan S, De Graaf CA, Codrington R, Rabbitts TH, Jane SM, Curtis DJ. 2010. The Lmo2 Oncogene Initiates Leukemia in Mice by Inducing Thymocyte Self-Renewal. Science. 327: 879.","pubmedId":"","doi":"10.1126/science.1182378"},{"reference":"Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, Takai K, et al., Werb Z. 2015. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature. 526: 131.","pubmedId":"","doi":"10.1038/nature15260"},{"reference":"Celia Terrassa T, Kang Y. 2016. Distinctive properties of metastasis-initiating cells. Genes & Development. 30: 892.","pubmedId":"","doi":"10.1101/gad.277681.116"},{"reference":"Hibino S, Kawazoe T, Kasahara H, Itoh S, Ishimoto T, Sakata Yanagimoto M, Taniguchi K. 2021. Inflammation-Induced Tumorigenesis and Metastasis. International Journal of Molecular Sciences. 22: 5421.","pubmedId":"","doi":"10.3390/ijms22115421"},{"reference":"Coussens LM, Werb Z. 2002. Inflammation and cancer. Nature. 420: 860.","pubmedId":"","doi":"10.1038/nature01322"},{"reference":"Quail DF, Joyce JA. 2013. Microenvironmental regulation of tumor progression and metastasis. Nature Medicine. 19: 1423.","pubmedId":"","doi":"10.1038/nm.3394"},{"reference":"Hillion J, Dhara S, Sumter TF, Mukherjee M, Di Cello F, Belton A, et al., Resar LMS. 2008. The High-Mobility Group A1a/Signal Transducer and Activator of Transcription-3 Axis: An Achilles Heel for Hematopoietic Malignancies?. Cancer Research. 68: 10121.","pubmedId":"","doi":"10.1158/0008-5472.CAN-08-2121"},{"reference":"Galoczova M, Coates P, Vojtesek B. 2018. STAT3, stem cells, cancer stem cells and p63. Cellular & Molecular Biology Letters. 23: 12.","pubmedId":"","doi":"10.1186/s11658-018-0078-0"},{"reference":"Ma JH, Qin L, Li X. 2020. Role of STAT3 signaling pathway in breast cancer. Cell communication and signaling: CCS. 18: 33.","pubmedId":"","doi":"10.1186/s12964-020-0527-z"},{"reference":"Ventura A, Meissner A, Dillon CP, Mc Manus M, Sharp PA, Van Parijs L, Jaenisch R, Jacks T. 2004. Cre-lox-regulated conditional RNA interference from transgenes. Proceedings of the National Academy of Sciences. 101: 10380.","pubmedId":"","doi":"10.1073/pnas.0403954101"},{"reference":"Milton Harris L, Jeeves M, Walker SA, Ward SE, Mancini EJ. 2020. Small molecule inhibits T-cell acute lymphoblastic leukaemia oncogenic interaction through conformational modulation of LMO2. Oncotarget. 11: 1737.","pubmedId":"","doi":"10.18632/oncotarget.27580"},{"reference":"Kim SM, Kwon OJ, Hong YK, Kim JH, Solca F, Ha SJ, et al., Cho BC. 2012. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Molecular Cancer Therapeutics. 11: 2254.","pubmedId":"","doi":"10.1158/1535-7163.MCT-12-0311"},{"reference":"Carpenter RL, Lo HW. 2014. STAT3 Target Genes Relevant to Human Cancers. Cancers. 6: 897.","pubmedId":"","doi":"10.3390/cancers6020897"},{"reference":"Park CG, Choi SH, Lee SY, Eun K, Park MG, Jang J, et al., Kim H. 2022. Cytoplasmic LMO2-LDB1 Complex Activates STAT3 Signaling through Interaction with gp130-JAK in Glioma Stem Cells. Cells. 11: 2031.","pubmedId":"","doi":"10.3390/cells11132031"},{"reference":"Sikandar SS, Gulati GS, Antony J, Fetter I, Kuo AH, Ho WHD, et al., Clarke MF. 2022. Identification of a minority population of LMO2+ breast cancer cells that integrate into the vasculature and initiate metastasis. Science Advances. 8: eabm3548.","pubmedId":"","doi":"10.1126/sciadv.abm3548"},{"reference":"Bery N, Bataille CJR, Russell A, Hayes A, Raynaud F, Milhas S, et al., Rabbitts TH. 2021. A cell-based screening method using an intracellular antibody for discovering small molecules targeting the translocation protein LMO2. Science Advances. 7: eabg1950.","pubmedId":"","doi":"10.1126/sciadv.abg1950"},{"reference":"Ma J, Cao X. 2006. Regulation of Stat3 nuclear import by importin α5 and importin α7 via two different functional sequence elements. Cellular Signalling. 18: 1117.","pubmedId":"","doi":"10.1016/j.cellsig.2005.06.016"},{"reference":"Qin S, Zou Y, Zhang CL. 2013. Cross-talk between KLF4 and STAT3 regulates axon regeneration. Nature Communications. 4: 2633.","pubmedId":"","doi":"10.1038/ncomms3633"},{"reference":"Wu Y, Diab I, Zhang X, Izmailova ES, Zehner ZE. 2004. Stat3 enhances vimentin gene expression by binding to the antisilencer element and interacting with the repressor protein, ZBP-89. Oncogene. 23: 168.","pubmedId":"","doi":"10.1038/sj.onc.1207003"},{"reference":"Read KA, Powell MD, Baker CE, Sreekumar BK, Ringel Scaia VM, Bachus H, et al., Oestreich KJ. 2017. Integrated STAT3 and Ikaros Zinc Finger Transcription Factor Activities Regulate Bcl-6 Expression in CD4+ Th Cells. The Journal of Immunology. 199: 2377.","pubmedId":"","doi":"10.4049/jimmunol.1700106"},{"reference":"Nakayama K, Kim KW, Miyajima A. 2002. A novel nuclear zinc finger protein EZI enhances nuclear retention and transactivation of STAT3. The EMBO Journal. 21: 6174.","pubmedId":"","doi":"10.1093/emboj/cdf596"},{"reference":"El Omari K, Hoosdally SJ, Tuladhar K, Karia D, Vyas P, Patient R, Porcher C, Mancini EJ. 2011. Structure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complex. Blood. 117: 2146.","pubmedId":"","doi":"10.1182/blood-2010-07-293357"},{"reference":"Liu L, Mc Bride KM, Reich NC. 2005. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-α3. Proceedings of the National Academy of Sciences. 102: 8150.","pubmedId":"","doi":"10.1073/pnas.0501643102"},{"reference":"Zhang G, Chen X, Yu C, Cui L, Chen N, Yi G, et al., Zhou Y. 2024. FNIP1 suppresses colorectal cancer progression through inhibiting STAT3 phosphorylation and nuclear translocation. iScience. 27: 110730.","pubmedId":"","doi":"10.1016/j.isci.2024.110730"},{"reference":"Chen Q, Hu Q, Chen Y, Shen N, Zhang N, Li A, Li L, Li J. 2023. PRMT6 methylation of STAT3 regulates tumor metastasis in breast cancer. Cell Death & Disease. 14: 655.","pubmedId":"","doi":"10.1038/s41419-023-06148-6"},{"reference":"Huang Y, Wang J, Cao F, Jiang H, Li A, Li J, et al., Lu Y. 2017. SHP2 associates with nuclear localization of STAT3: significance in progression and prognosis of colorectal cancer. Scientific Reports. 7: 17597.","pubmedId":"","doi":"10.1038/s41598-017-17604-7"},{"reference":"Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, et al., O Callaghan CJ. 2016. A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): the CCTG/AGITG CO.23 trial. Annals of Oncology. 27: vi150.","pubmedId":"","doi":"10.1093/annonc/mdw370.03"},{"reference":"Tolcher A, Flaherty K, Shapiro GI, Berlin J, Witzig T, Habermann T, et al., Cote GM. 2018. A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers. The Oncologist. 23: 658.","pubmedId":"","doi":"10.1634/theoncologist.2017-0325"},{"reference":"Ogura M, Uchida T, Terui Y, Hayakawa F, Kobayashi Y, Taniwaki M, et al., Hatake K. 2015. Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. Cancer Science. 106: 896.","pubmedId":"","doi":"10.1111/cas.12683"},{"reference":"Oh DY, Lee SH, Han SW, Kim MJ, Kim TM, Kim TY, et al., Bang YJ. 2015. Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. Cancer Research and Treatment. 47: 607.","pubmedId":"","doi":"10.4143/crt.2014.249"},{"reference":"Feldman T. 2024. Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors. 66th ASH Annual Meeting","pubmedId":"","doi":""},{"reference":"Hong DS, Younes A, Fayad L, Fowler NH, Hagemeister FB, Mistry R, et al., Kurzrock R. 2013. A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers.. Journal of Clinical Oncology. 31: 8523.","pubmedId":"","doi":"10.1200/jco.2013.31.15_suppl.8523"},{"reference":"Schindler C, Jr JED. 1995. TRANSCRIPTIONAL RESPONSES TO POLYPEPTIDE LIGANDS: The JAK-STAT Pathway. Annual Review of Biochemistry. 64: 621.","pubmedId":"","doi":"10.1146/annurev.bi.64.070195.003201"},{"reference":"Rubio S, Molinuevo R, Sanz Gomez N, Zomorrodinia T, Cockrum CS, Luong E, et al., Hinck L. 2024. Nuclear VANGL2 Inhibits Lactogenic Differentiation. Cells. 13: 222.","pubmedId":"","doi":"10.3390/cells13030222"},{"reference":"Baghirova S, Hughes BG, Hendzel MJ, Schulz R. 2015. Sequential fractionation and isolation of subcellular proteins from tissue or cultured cells. MethodsX. 2: 440.","pubmedId":"","doi":"10.1016/j.mex.2015.11.001"},{"reference":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. 2025. Cancer statistics, 2025. CA: A Cancer Journal for Clinicians. 75: 10.","pubmedId":"","doi":"10.3322/caac.21871"}],"title":"LMO2 regulates STAT3 localization to the nucleus in breast cancer cells
","reviews":[{"reviewer":{"displayName":"Brad Doble"},"openAcknowledgement":false,"status":{"submitted":true}}],"curatorReviews":[]},{"id":"8d59d8e5-ee1e-401e-80c6-12e8fcba0b82","decision":"edit","abstract":"STAT3 phosphorylation and transcriptional activity promote breast cancer growth and metastasis. We have previously reported that the transcriptional adaptor LMO2 is required for metastasis in breast cancer and promotes STAT3-JAK2 interaction, leading to STAT3 phosphorylation in metastasis-initiating cells. Here, we find that constitutively activated STAT3 is insufficient to drive metastasis in the absence of LMO2. Mechanistically, we find that LMO2 is required not only for STAT3 phosphorylation in the cytoplasm but also for STAT3 translocation to the nucleus. These data suggest that LMO2 promotes STAT3 activation and localization to the nucleus in breast cancer cells.
","acknowledgements":"We thank Benjamin Abrams, UCSC Life Sciences Microscopy Center, RRID: SCR_021135 for technical support during image acquisition and processing.
","authors":[{"affiliations":["University of California, Santa Cruz","University of California, Santa Cruz"],"departments":["Molecular, Cell & Developmental Biology","Institute for the Biology of Stem Cells"],"credit":["dataCuration","investigation","methodology","visualization","writing_originalDraft","formalAnalysis","conceptualization"],"email":"ifetter@ucsc.edu","firstName":"Isobel J","lastName":"Fetter","submittingAuthor":false,"correspondingAuthor":false,"equalContribution":false,"WBId":null,"orcid":null},{"affiliations":["University of California, Santa Cruz"],"departments":["Molecular, Cell & Developmental Biology"],"credit":["dataCuration","investigation","methodology"],"email":"vharoaco@ucsc.edu","firstName":"Veronica","lastName":"Haro Acosta","submittingAuthor":false,"correspondingAuthor":false,"equalContribution":false,"WBId":null,"orcid":null},{"affiliations":["University of California, Santa Cruz"],"departments":["Molecular, Cell & Developmental Biology"],"credit":["investigation","methodology"],"email":"sparecadan@gmail.com","firstName":"Sachin ","lastName":"Parecadan","submittingAuthor":false,"correspondingAuthor":false,"equalContribution":false,"WBId":null,"orcid":null},{"affiliations":["University of California, Santa Cruz","University of California, Santa Cruz","University of California, Santa Cruz"],"departments":["Molecular, Cell & Developmental Biology","Institute for the Biology of Stem Cells","Genomics Institute",""],"credit":["conceptualization","formalAnalysis","fundingAcquisition","investigation","project","supervision","writing_originalDraft"],"email":"ssikanda@ucsc.edu","firstName":"Shaheen S","lastName":"Sikandar","submittingAuthor":true,"correspondingAuthor":true,"equalContribution":false,"WBId":null,"orcid":null}],"awards":[{"awardId":" R37CA269754","funderName":"National Cancer Institute (United States)","awardRecipient":"Shaheen Sikandar"},{"awardId":"5T32GM133391","funderName":"National Institutes of Health (United States)","awardRecipient":"Isobel Fetter"},{"awardId":"EDUC4-12759","funderName":"California Institute for Regenerative Medicine (United States)","awardRecipient":"Isobel Fetter"}],"conflictsOfInterest":"The authors declare that there are no conflicts of interest present.
","dataTable":{"url":null},"extendedData":[],"funding":"","image":{"url":"https://portal.micropublication.org/uploads/49cde8b98d92c842d1d698171583afee.png"},"imageCaption":"(A) Schematic of aSTAT3 and shLMO2 expression in MDA-MB-468 cells followed by orthotopic transplant in NSG mice to evaluate tumor burden and metastasis. (B) Immunoblotting of MDA-MB-468 cells transduced with either control (pSicoR) or constitutively active STAT3 plasmid. (C) Tumor weight in control (pRSI12/pSicoR), shLMO2 (shLMO2/pSicoR), aSTAT3 (pRSI12/aSTAT3), and shLMO2/aSTAT3 tumors generated from MDA-MB-468 cell xenografts (n = 5 mice per group). (D) Representative fluorescent images of spontaneous RFP+/GFP+ lung metastases from mice with control, shLMO2, aSTAT3, and shLMO2/aSTAT3 tumors in (B). (E) Quantification of metastases in (D). Data shown as mean ± standard deviation. (F) Representative immunoblot of cytoplasmic and nuclear fractions of MDA-MB-468 cells transduced with control (pRSI12/pSicoR), shLMO2 (shLMO2/pSicoR), aSTAT3 (pRSI12/aSTAT3), and shLMO2/aSTAT3 plasmids, probed for phospho-STAT3 (Tyr705), STAT3, FLAG, Lamin B, and β-Tubulin 1. Densitometric values for each representative blot are below the respective band. (G) Quantification of cytoplasmic phosphor-STAT3 (Tyr705) as shown in (F), normalized to β-Tubulin 1 cytoplasmic loading control. (H) Quantification of nuclear phospho-STAT3 (Tyr705) as shown in (F), normalized to Lamin B nuclear loading control. For G-H, n = 5 biological replicates. (I) Quantification of cytoplasmic FLAG as shown in (F), normalized to β-Tubulin 1 cytoplasmic loading control. (J) Quantification of nuclear FLAG as shown in (F), normalized to Lamin B nuclear loading control. For I-J, n = 3 biological replicates. Statistical significance was calculated with ordinary 1-way ANOVA with multiple comparisons (C, E, G-H) and unpaired t-tests (I-J).
","imageTitle":"LMO2 regulates STAT3 localization to the nucleus in breast cancer cells
","methods":"Cell Line Generation
MDA-MB-468 and HEK293T cells were obtained from the American Type Culture Collection. Cells were cultured in DMEM supplemented with penicillin (120 μg/mL), streptomycin (100 μg/mL), amphotericin B (0.25 μg/mL), and 10% FBS. LMO2 shRNA targeting the 3′UTR (5′-GACGCATTTCGGTTGAGAA-3′) was cloned into the pRSI12-U6-(sh)-HTS4-UbiC-TagRFP-2A-Puro shRNA expression vector (Cellecta). The pRSI12 empty vector was used as a control. EF.STAT3C.Ubc.GFP was a gift from Linzhao Cheng (Addgene plasmid #24983; http://n2t.net/addgene:24983; RRID: Addgene_24983). pSicoR was a gift from Tyler Jacks (Addgene plasmid #11579; http://n2t.net/addgene:11579; RRID: Addgene_11579) and was used as an empty vector control for the aSTAT3 plasmid. Viruses were produced in HEK293T cells using the second-generation lentiviral system and transfection using Lipofectamine 2000 (Life Technologies). Supernatants were collected at 48 and 72 hours, filtered with a 0.45-μm filter, and precipitated with lentivirus precipitation solution (Alstem LLC) per the manufacturer’s instructions. Viral titers were determined by flow cytometry analyses of HEK293T cells infected with serial dilutions of concentrated virus.
Mouse Models
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) (stock #005557) mice were purchased from The Jackson Laboratory and bred at the University of California Santa Cruz (UCSC). All mice used for this study were maintained at the UCSC Animal Facility in accordance with the guidelines set forth by UCSC and the Institutional Animal Care and Use Committee (Protocol number SIKAS2010).
Xenografts
To prepare cells for orthotopic injection, cells were trypsinized with standard protocols, and live cell counts were assessed by Trypan Blue staining. Each cell line was resuspended in DMEM containing 40% Matrigel and subcutaneously injected into the fourth abdominal fat pads on one side of female NSG mice. 100,000 cells were used for each injection. Mice were monitored every week for tumor growth. All mice were euthanized if tumor growth reached the endpoint (1500 mm3). Tumor size was measured using digital calipers. Tumors were harvested and weighed, and lungs were harvested and placed in PBS on ice. The lungs were then imaged in brightfield, RFP, and GFP on a Keyence Biorevo BZ-9000 digital widefield microscope. The RFP and GFP channels were then merged with FIJI (Schindelin et al., 2012), and RFP/GFP double positive lung metastases were manually counted.
Subcellular fractionation
Whole cell lysates were generated by lysis with radioimmunoprecipitation assay (RIPA) buffer, along with protease and phosphatase inhibitor cocktails (Thermo Fisher Scientific). Subcellular fractionation was performed as described previously (Baghirova et al., 2015; Rubio et al., 2024). Briefly, cultured cells were washed with room temperature PBS before detachment with trypsin. Cells were resuspended in DMEM with 10% FBS and pelleted at 500 x g. Increasingly strong detergents were used to lyse the cells, and the cytoplasmic fraction, the membrane-bound organelle fraction, and finally the nuclear fraction were collected from the supernatant. After the supernatant was collected for each fraction, the remaining cell material was washed 3 times with the respective lysis buffer to remove any remaining protein before the next lysis step. Protein concentration was measured with the Pierce BCA Protein Assay Kit (Thermo Scientific).
Western Blotting
For each sample, 20 μg of protein lysate was added to 10 μL 4x NuPAGE LDS buffer with 4% β-mercaptoethanol, then boiled at 95°C for 5 minutes before gel electrophoresis. SDS-PAGE gels were run at 100 V for 70 min, then transferred onto polyvinylidene difluoride membranes (#IPFL00010, Millipore, Billerica, MA) at 70 V for 90 min. Membranes were blocked with 5% BSA/Tris-buffered saline–Tween 0.1% (TBST) for 1 hour at RT and then subsequently probed with primary antibodies diluted at 1:1000 in 5% BSA/Tris-buffered saline–Tween 0.1% (TBST) overnight at 4°C. Membranes were then incubated in secondary antibodies containing HRP for 1 hour at RT. Clarity Western ECL Substrate (Bio-Rad) was used to enable visualization on the Bio-Rad ChemiDoc. Washes in between incubations were done for 10 min × 3 using TBST.
Immunoblot Quantification
Western blot bands were quantified using FIJI (Schindelin et al., 2012) software and normalized to controls as indicated in the figure legend. Rectangular regions of interest were drawn over lanes, then the peaks were plotted using the “Plot Lanes” tool. Vertical lines were then drawn to define peaks of interest, then the wand tool was used to measure the size of each peak. Densitometric values for phospho-STAT3 were normalized to values for β-Tubulin 1, STAT3, or Lamin B as noted in figure legends. Each sample was normalized to the loading control in the same lane. For example, the cytoplasmic phospho-STAT3 value for the control condition was divided by the β-Tubulin 1 value for the control on the same gel.
Statistical Analysis
All graphs show the mean, and error bars indicate standard deviations. P values are calculated using ordinary 1-way ANOVA with multiple comparisons and unpaired t-tests with GraphPad Prism. For animal studies, sample size was not predetermined to ensure adequate power to detect a prespecified effect size, no animals were excluded from analyses, and investigators were not blinded to group allocation during experiments.
","reagents":"Cell Line | Genotype | Available From |
MDA-MB-468 | Homo sapiens, isolated from a pleural effusion of a female patient with metastatic adenocarcinoma of the breast | ATCC |
HEK293T | Homo sapiens, derived from embryonic kidney 293 cells, contains SV40 T-antigen | ATCC |
Plasmid | Description |
pSicoR | pSicoR was a gift from Tyler Jacks (Addgene plasmid #11579; http://n2t.net/addgene:11579; RRID: Addgene_11579) |
aSTAT3 | EF.STAT3C.Ubc.GFP was a gift from Linzhao Cheng (Addgene plasmid #24983; http://n2t.net/addgene:24983; RRID: Addgene_24983) |
pRSI12 | pRSI12-U6-(sh)-HTS4-UbiC-TagRFP-2A-Puro shRNA expression vector (Cellecta) |
shLMO2 | LMO2 shRNA targeting the 3′UTR (5′-GACGCATTTCGGTTGAGAA-3′) was cloned into the pRSI12 shRNA expression vector (Cellecta) |
Animal Strain | Genotype | Available From |
NSG Mus musculus | NOD.Cg-PrkdcscidIl2rgtm1Wjl/Szj | Jackson Laboratory (stock #005557) |
Antibody | Animal and Clonality | Immunogen | Concentration |
anti-FLAG | Rabbit polyclonal (Sigma-Aldrich #F7425) | DYKDDDDK | 1:2500 |
anti-STAT3 | Mouse monoclonal, clone 9D8 (Abcam #ab119352) | peptide within human STAT3 aa 650 to the C-terminus | 1:1000 |
anti-pSTAT3 (Y705) | Rabbit monoclonal, clone D3A7 (Cell Signaling Technology #9145) | synthetic phosphopeptide corresponding to residues surrounding Tyr705 of mouse Stat3 | 1:1000 |
anti-Lamin B | Goat polyclonal (Santa Cruz Biotechnology #sc-6216) | peptide mapping at the C-terminus of human Lamin B1 | 1:1000 |
anti-β-Tubulin 1 | Mouse monoclonal, clone SAP.4G5 (Sigma-Aldrich #T7816) | synthetic peptide corresponding to the C-terminal sequence of β-tubulin isotype I | 1:1000 |
anti-β-Actin, HRP conjugated | Mouse monoclonal, clone BA3R (Invitrogen #MA5-15739-HRP) | β-actin N-terminal peptide | 1:5000 |
anti-mouse IgG, HRP conjugated | Horse polyclonal (Cell Signaling Technology #7076) | mouse IgG heavy and light chain | 1:5000 |
anti-rabbit IgG, HRP conjugated | Goat polyclonal (Cell Signaling Technology #7074) | rabbit IgG heavy and light chain | 1:5000 |
anti-goat IgG, HRP conjugated | Donkey polyclonal (Jackson ImmunoResearch #705-035-147) | goat IgG heavy and light chain | 1:5000 |
Metastasis is the leading cause of breast cancer-related deaths, making it imperative to develop strategies to target metastasis (Dillekås et al., 2019; Siegel et al., 2025). It is well established that breast tumors contain heterogeneous populations, with only a small subset of tumor cells exhibiting tumor-initiating and metastatic capacity (Lawson et al., 2015; Celià-Terrassa and Kang, 2016; Sikandar et al., 2017). Understanding molecular mechanisms regulating metastasis-initiating cells (MICs) will broaden potential targets and treatment strategies for breast cancer.
Previous studies have demonstrated that inflammatory cytokines such as IL6 and TNFɑ activate the JAK/STAT and NFκB pathways, resulting in transcriptional changes leading to tumorigenesis and metastasis (Coussens and Werb, 2002; Quail and Joyce, 2013; Hibino et al., 2021). STAT3 is phosphorylated by JAK2, homodimerizes to move to the nucleus and regulate transcription of its target genes, promoting proliferation, survival, and self-renewal (Schindler and Jr, 1995).
We recently identified a population of MICs in breast cancer that express LMO2, a transcriptional adaptor protein in hematopoietic stem cells and a T-cell oncogene (Yamada et al., 1998; McCormack et al., 2010). Knocking down LMO2 did not affect the growth of primary tumors, but significantly reduced the number of circulating tumor cells and lung metastases (Sikandar et al., 2022). Mechanistically, we found that LMO2 binds to the transcription factor STAT3 and is required for STAT3 phosphorylation in breast cancer cells (Sikandar et al., 2022). Consistent with our previous findings, another study showed LMO2 activates STAT3 signaling in glioblastoma to increase stem-like activity of cancer cells, suggesting that LMO2 activates STAT3 signaling in multiple cancers (Park et al., 2022). Here, we further investigate interactions between LMO2 and STAT3 during breast cancer metastasis by combining constitutively activated STAT3 with the loss of LMO2.
STAT3 is constitutively activated in several cancers, including breast cancer (Kim et al., 2012; Carpenter and Lo, 2014; Galoczova et al., 2018; J.-H. Ma et al., 2020). Hence, we wanted to test whether activated STAT3 (aSTAT3) can rescue the effect of LMO2 knockdown. To test whether constitutively active STAT3 (aSTAT3) is sufficient to rescue the decreased metastatic potential observed upon LMO2 knockdown, we first obtained a FLAG-tagged aSTAT3 construct (Hillion et al., 2008) and confirmed its expression by immunoblotting (Fig. 1B). We then generated four cell lines combining LMO2 knockdown and aSTAT3 and their respective controls (Ventura et al., 2004). These cell lines were orthotopically transplanted into the mammary fat pad of female NSG mice, and tumor growth was monitored over time (Fig. 1A). We found that there is no difference in tumor growth between the control, shLMO2, aSTAT3, or aSTAT3/shLMO2 (Fig. 1C). This is consistent with our previous findings that LMO2 knockdown significantly reduced metastasis, but did not impact tumor growth (Sikandar et al., 2022). We also found that aSTAT3 did not increase the number of metastases (Fig. 1D-E). Importantly, mice with shLMO2/aSTAT3 tumors have reduced metastasis similar to the mice with LMO2 knockdown tumors, suggesting that the combination of constitutively active STAT3 and LMO2 knockdown is insufficient to rescue metastasis (Fig. 1D-E).
As LMO2 is an adaptor protein and facilitates the formation of transcription factor complexes (Yamada et al., 1998), we next wanted to understand whether LMO2 is required for STAT3 localization to the nucleus. Hence, we performed subcellular fractionation and immunoblotting to find that, as expected, pSTAT3 is primarily located in the nucleus in the control and aSTAT3 cell lines (Fig. 1F). We observed an increase in cytoplasmic pSTAT3 in the shLMO2/aSTAT3 cells compared to the control, suggesting that while the aSTAT3 construct increased pSTAT3, a significant amount of pSTAT3 remains in the cytoplasm and does not translocate to the nucleus. Indeed, in the nuclear fractions of both the shLMO2 and shLMO2/aSTAT3 conditions, there is a significant reduction in nuclear pSTAT3 compared to the control conditions (Fig. 1H). Because the aSTAT3 construct can dimerize in absence of phosphorylation and translocate to the nucleus (Hillion et al., 2008), we also probed for FLAG-tag to determine whether LMO2 modulates translocation of aSTAT3. While FLAG-tagged STAT3 is detected in both the cytoplasm and nucleus of aSTAT3 and shLMO2/aSTAT3 cells (Fig. 1F), the amount of aSTAT3 (as measured by FLAG expression) is significantly higher in the cytoplasm and reduced in the nucleus in shLMO2/aSTAT3 cells as compared to aSTAT3 control (Fig. 1I, J). This suggests that LMO2 regulates STAT3 nuclear localization, even when STAT3 is constitutively active. In summary, these data suggest a novel role for LMO2 in breast cancer cells; in addition to stabilizing JAK2-STAT3 interactions to promote phosphorylation (Sikandar et al., 2022), LMO2 actively facilitates STAT3 localization to the nucleus.
STAT3 phosphorylation and nuclear localization are associated with tumorigenesis and metastasis in multiple cancers, with increased nuclear STAT3 leading to reduced overall survival in patients (Huang et al., 2017; Chen et al., 2023; Zhang et al., 2024). STAT3 can localize to the nucleus without phosphorylation, but phosphorylation is required for STAT3’s transcription factor activity (Liu et al., 2005). We observed a significant reduction in nuclear pSTAT3 in shLMO2 and shLMO2/aSTAT3 conditions (Fig. 1H), suggesting that LMO2 promotes STAT3’s nuclear localization and thus its transcriptional activity. STAT3 is imported into the nucleus primarily through importin-ɑ3 (KPNA4) or importin-ɑ5 (KPNA1) in association with importin-β1 (KPNB1) (Liu et al., 2005; J. Ma and Cao, 2006). Some FLAG-tagged STAT3 is still found in the nucleus when LMO2 is knocked down but significantly reduced compared to control cells (Fig. 1J). Structurally, LMO2 is composed of 2 LIM fingers, each containing 2 zinc finger motifs (El Omari et al., 2011). Interestingly, other zinc finger-containing proteins such as EZI (Nakayama et al., 2002), ZBP-89 (Wu et al., 2004), KLF4 (Qin et al., 2013), and IKZF1 and IKZF3 (Read et al., 2017) have been shown to associate with and modulate nuclear localization of STAT3.
STAT3 signaling is an appealing target for treating cancer. Multiple STAT3 inhibitors have been investigated in clinical trials with various efficacies and tolerances (Hong et al., 2013; Ogura et al., 2015; Oh et al., 2015; Jonker et al., 2016; Tolcher et al., 2018; Feldman, 2024), but there are currently no FDA-approved therapies targeting STAT3. Inhibiting STAT3 signaling can lead to off-target toxicity, so targeting STAT3 only in cancer cells could improve outcomes. Since the oncogenic effects depend on STAT3’s nuclear localization, disrupting its nuclear import represents an alternative therapeutic strategy. Disruption of LMO2-STAT3 interactions using newly developed inhibitors for LMO2 could prevent nuclear accumulation and suppress STAT3-driven transcription (Milton-Harris et al., 2020; Bery et al., 2021). Therapeutically, this approach offers a potential strategy to selectively target constitutively active STAT3 in tumors while sparing transient STAT3 activation in normal tissues. However, it is also possible that LMO2 has additional functions independent of its interaction with STAT3 that contribute to metastasis. Future structure-function studies will determine how LMO2 promotes STAT3 localization to the nucleus in metastasis-initiating cells and whether LMO2 binds to additional molecules to modulate metastasis in breast cancer.
","references":[{"reference":"Sikandar SS, Kuo AH, Kalisky T, Cai S, Zabala M, Hsieh RW, et al., Clarke MF. 2017. Role of epithelial to mesenchymal transition associated genes in mammary gland regeneration and breast tumorigenesis. Nature Communications. 8: 1669.","pubmedId":"","doi":"10.1038/s41467-017-01666-2"},{"reference":"Dillekas H, Rogers MS, Straume O. 2019. Are 90% of deaths from cancer caused by metastases?. Cancer Medicine. 8: 5574.","pubmedId":"","doi":"10.1002/cam4.2474"},{"reference":"Yamada Y, Warren AJ, Dobson C, Forster A, Pannell R, Rabbitts TH. 1998. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proceedings of the National Academy of Sciences. 95: 3890.","pubmedId":"","doi":"10.1073/pnas.95.7.3890"},{"reference":"Mc Cormack MP, Young LF, Vasudevan S, De Graaf CA, Codrington R, Rabbitts TH, Jane SM, Curtis DJ. 2010. The Lmo2 Oncogene Initiates Leukemia in Mice by Inducing Thymocyte Self-Renewal. Science. 327: 879.","pubmedId":"","doi":"10.1126/science.1182378"},{"reference":"Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, Takai K, et al., Werb Z. 2015. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature. 526: 131.","pubmedId":"","doi":"10.1038/nature15260"},{"reference":"Celia Terrassa T, Kang Y. 2016. Distinctive properties of metastasis-initiating cells. Genes & Development. 30: 892.","pubmedId":"","doi":"10.1101/gad.277681.116"},{"reference":"Hibino S, Kawazoe T, Kasahara H, Itoh S, Ishimoto T, Sakata Yanagimoto M, Taniguchi K. 2021. Inflammation-Induced Tumorigenesis and Metastasis. International Journal of Molecular Sciences. 22: 5421.","pubmedId":"","doi":"10.3390/ijms22115421"},{"reference":"Coussens LM, Werb Z. 2002. Inflammation and cancer. Nature. 420: 860.","pubmedId":"","doi":"10.1038/nature01322"},{"reference":"Quail DF, Joyce JA. 2013. Microenvironmental regulation of tumor progression and metastasis. Nature Medicine. 19: 1423.","pubmedId":"","doi":"10.1038/nm.3394"},{"reference":"Hillion J, Dhara S, Sumter TF, Mukherjee M, Di Cello F, Belton A, et al., Resar LMS. 2008. The High-Mobility Group A1a/Signal Transducer and Activator of Transcription-3 Axis: An Achilles Heel for Hematopoietic Malignancies?. Cancer Research. 68: 10121.","pubmedId":"","doi":"10.1158/0008-5472.CAN-08-2121"},{"reference":"Galoczova M, Coates P, Vojtesek B. 2018. STAT3, stem cells, cancer stem cells and p63. Cellular & Molecular Biology Letters. 23: 12.","pubmedId":"","doi":"10.1186/s11658-018-0078-0"},{"reference":"Ma JH, Qin L, Li X. 2020. Role of STAT3 signaling pathway in breast cancer. Cell communication and signaling: CCS. 18: 33.","pubmedId":"","doi":"10.1186/s12964-020-0527-z"},{"reference":"Ventura A, Meissner A, Dillon CP, Mc Manus M, Sharp PA, Van Parijs L, Jaenisch R, Jacks T. 2004. Cre-lox-regulated conditional RNA interference from transgenes. Proceedings of the National Academy of Sciences. 101: 10380.","pubmedId":"","doi":"10.1073/pnas.0403954101"},{"reference":"Milton Harris L, Jeeves M, Walker SA, Ward SE, Mancini EJ. 2020. Small molecule inhibits T-cell acute lymphoblastic leukaemia oncogenic interaction through conformational modulation of LMO2. Oncotarget. 11: 1737.","pubmedId":"","doi":"10.18632/oncotarget.27580"},{"reference":"Kim SM, Kwon OJ, Hong YK, Kim JH, Solca F, Ha SJ, et al., Cho BC. 2012. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Molecular Cancer Therapeutics. 11: 2254.","pubmedId":"","doi":"10.1158/1535-7163.MCT-12-0311"},{"reference":"Carpenter RL, Lo HW. 2014. STAT3 Target Genes Relevant to Human Cancers. Cancers. 6: 897.","pubmedId":"","doi":"10.3390/cancers6020897"},{"reference":"Park CG, Choi SH, Lee SY, Eun K, Park MG, Jang J, et al., Kim H. 2022. Cytoplasmic LMO2-LDB1 Complex Activates STAT3 Signaling through Interaction with gp130-JAK in Glioma Stem Cells. Cells. 11: 2031.","pubmedId":"","doi":"10.3390/cells11132031"},{"reference":"Sikandar SS, Gulati GS, Antony J, Fetter I, Kuo AH, Ho WHD, et al., Clarke MF. 2022. Identification of a minority population of LMO2+ breast cancer cells that integrate into the vasculature and initiate metastasis. Science Advances. 8: eabm3548.","pubmedId":"","doi":"10.1126/sciadv.abm3548"},{"reference":"Bery N, Bataille CJR, Russell A, Hayes A, Raynaud F, Milhas S, et al., Rabbitts TH. 2021. A cell-based screening method using an intracellular antibody for discovering small molecules targeting the translocation protein LMO2. Science Advances. 7: eabg1950.","pubmedId":"","doi":"10.1126/sciadv.abg1950"},{"reference":"Ma J, Cao X. 2006. Regulation of Stat3 nuclear import by importin α5 and importin α7 via two different functional sequence elements. Cellular Signalling. 18: 1117.","pubmedId":"","doi":"10.1016/j.cellsig.2005.06.016"},{"reference":"Qin S, Zou Y, Zhang CL. 2013. Cross-talk between KLF4 and STAT3 regulates axon regeneration. Nature Communications. 4: 2633.","pubmedId":"","doi":"10.1038/ncomms3633"},{"reference":"Wu Y, Diab I, Zhang X, Izmailova ES, Zehner ZE. 2004. Stat3 enhances vimentin gene expression by binding to the antisilencer element and interacting with the repressor protein, ZBP-89. Oncogene. 23: 168.","pubmedId":"","doi":"10.1038/sj.onc.1207003"},{"reference":"Read KA, Powell MD, Baker CE, Sreekumar BK, Ringel Scaia VM, Bachus H, et al., Oestreich KJ. 2017. Integrated STAT3 and Ikaros Zinc Finger Transcription Factor Activities Regulate Bcl-6 Expression in CD4+ Th Cells. The Journal of Immunology. 199: 2377.","pubmedId":"","doi":"10.4049/jimmunol.1700106"},{"reference":"Nakayama K, Kim KW, Miyajima A. 2002. A novel nuclear zinc finger protein EZI enhances nuclear retention and transactivation of STAT3. The EMBO Journal. 21: 6174.","pubmedId":"","doi":"10.1093/emboj/cdf596"},{"reference":"El Omari K, Hoosdally SJ, Tuladhar K, Karia D, Vyas P, Patient R, Porcher C, Mancini EJ. 2011. Structure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complex. Blood. 117: 2146.","pubmedId":"","doi":"10.1182/blood-2010-07-293357"},{"reference":"Liu L, Mc Bride KM, Reich NC. 2005. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-α3. Proceedings of the National Academy of Sciences. 102: 8150.","pubmedId":"","doi":"10.1073/pnas.0501643102"},{"reference":"Zhang G, Chen X, Yu C, Cui L, Chen N, Yi G, et al., Zhou Y. 2024. FNIP1 suppresses colorectal cancer progression through inhibiting STAT3 phosphorylation and nuclear translocation. iScience. 27: 110730.","pubmedId":"","doi":"10.1016/j.isci.2024.110730"},{"reference":"Chen Q, Hu Q, Chen Y, Shen N, Zhang N, Li A, Li L, Li J. 2023. PRMT6 methylation of STAT3 regulates tumor metastasis in breast cancer. Cell Death & Disease. 14: 655.","pubmedId":"","doi":"10.1038/s41419-023-06148-6"},{"reference":"Huang Y, Wang J, Cao F, Jiang H, Li A, Li J, et al., Lu Y. 2017. SHP2 associates with nuclear localization of STAT3: significance in progression and prognosis of colorectal cancer. Scientific Reports. 7: 17597.","pubmedId":"","doi":"10.1038/s41598-017-17604-7"},{"reference":"Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, et al., O Callaghan CJ. 2016. A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): the CCTG/AGITG CO.23 trial. Annals of Oncology. 27: vi150.","pubmedId":"","doi":"10.1093/annonc/mdw370.03"},{"reference":"Tolcher A, Flaherty K, Shapiro GI, Berlin J, Witzig T, Habermann T, et al., Cote GM. 2018. A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers. The Oncologist. 23: 658.","pubmedId":"","doi":"10.1634/theoncologist.2017-0325"},{"reference":"Ogura M, Uchida T, Terui Y, Hayakawa F, Kobayashi Y, Taniwaki M, et al., Hatake K. 2015. Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. Cancer Science. 106: 896.","pubmedId":"","doi":"10.1111/cas.12683"},{"reference":"Oh DY, Lee SH, Han SW, Kim MJ, Kim TM, Kim TY, et al., Bang YJ. 2015. Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. Cancer Research and Treatment. 47: 607.","pubmedId":"","doi":"10.4143/crt.2014.249"},{"reference":"Feldman T. 2024. Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors. 66th ASH Annual Meeting","pubmedId":"","doi":""},{"reference":"Hong DS, Younes A, Fayad L, Fowler NH, Hagemeister FB, Mistry R, et al., Kurzrock R. 2013. A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers.. Journal of Clinical Oncology. 31: 8523.","pubmedId":"","doi":"10.1200/jco.2013.31.15_suppl.8523"},{"reference":"Schindler C, Jr JED. 1995. TRANSCRIPTIONAL RESPONSES TO POLYPEPTIDE LIGANDS: The JAK-STAT Pathway. Annual Review of Biochemistry. 64: 621.","pubmedId":"","doi":"10.1146/annurev.bi.64.070195.003201"},{"reference":"Rubio S, Molinuevo R, Sanz Gomez N, Zomorrodinia T, Cockrum CS, Luong E, et al., Hinck L. 2024. Nuclear VANGL2 Inhibits Lactogenic Differentiation. Cells. 13: 222.","pubmedId":"","doi":"10.3390/cells13030222"},{"reference":"Baghirova S, Hughes BG, Hendzel MJ, Schulz R. 2015. Sequential fractionation and isolation of subcellular proteins from tissue or cultured cells. MethodsX. 2: 440.","pubmedId":"","doi":"10.1016/j.mex.2015.11.001"},{"reference":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. 2025. Cancer statistics, 2025. CA: A Cancer Journal for Clinicians. 75: 10.","pubmedId":"","doi":"10.3322/caac.21871"},{"reference":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al., Cardona. 2012. Fiji: an open-source platform for biological-image analysis. Nature Methods 9: 676-682.
","pubmedId":"22743772","doi":" 10.1038/nmeth.2019"},{"reference":"Hillion J, Dhara S, Sumter TF, Mukherjee M, Di Cello F, Belton A, et al., Resar LM. 2008. The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies? Cancer Res 68(24): 10121-7.
","pubmedId":"19074878","doi":""}],"title":"LMO2 regulates STAT3 localization to the nucleus in breast cancer cells
","reviews":[{"reviewer":{"displayName":"Brad Doble"},"openAcknowledgement":false,"status":{"submitted":true}}],"curatorReviews":[]},{"id":"634d74e8-ec98-4803-9c5e-fc455f8e48ef","decision":"edit","abstract":"STAT3 phosphorylation and transcriptional activity promote breast cancer growth and metastasis. We have previously reported that the transcriptional adaptor LMO2 is required for metastasis in breast cancer and promotes STAT3-JAK2 interaction, leading to STAT3 phosphorylation in metastasis-initiating cells. Here, we find that constitutively activated STAT3 is insufficient to drive metastasis in the absence of LMO2. Mechanistically, we find that LMO2 is required not only for STAT3 phosphorylation in the cytoplasm but also for STAT3 translocation to the nucleus. These data suggest that LMO2 promotes STAT3 activation and localization to the nucleus in breast cancer cells.
","acknowledgements":"We thank Benjamin Abrams, UCSC Life Sciences Microscopy Center, RRID: SCR_021135 for technical support during image acquisition and processing.
","authors":[{"affiliations":["University of California, Santa Cruz","University of California, Santa Cruz"],"departments":["Molecular, Cell & Developmental Biology","Institute for the Biology of Stem Cells"],"credit":["dataCuration","investigation","methodology","visualization","writing_originalDraft","formalAnalysis","conceptualization"],"email":"ifetter@ucsc.edu","firstName":"Isobel J","lastName":"Fetter","submittingAuthor":false,"correspondingAuthor":false,"equalContribution":false,"WBId":null,"orcid":null},{"affiliations":["University of California, Santa Cruz"],"departments":["Molecular, Cell & Developmental Biology"],"credit":["dataCuration","investigation","methodology"],"email":"vharoaco@ucsc.edu","firstName":"Veronica","lastName":"Haro Acosta","submittingAuthor":false,"correspondingAuthor":false,"equalContribution":false,"WBId":null,"orcid":null},{"affiliations":["University of California, Santa Cruz"],"departments":["Molecular, Cell & Developmental Biology"],"credit":["investigation","methodology"],"email":"sparecadan@gmail.com","firstName":"Sachin ","lastName":"Parecadan","submittingAuthor":false,"correspondingAuthor":false,"equalContribution":false,"WBId":null,"orcid":null},{"affiliations":["University of California, Santa Cruz","University of California, Santa Cruz","University of California, Santa Cruz"],"departments":["Molecular, Cell & Developmental Biology","Institute for the Biology of Stem Cells","Genomics Institute",""],"credit":["conceptualization","formalAnalysis","fundingAcquisition","investigation","project","supervision","writing_originalDraft"],"email":"ssikanda@ucsc.edu","firstName":"Shaheen S","lastName":"Sikandar","submittingAuthor":true,"correspondingAuthor":true,"equalContribution":false,"WBId":null,"orcid":null}],"awards":[{"awardId":" R37CA269754","funderName":"National Cancer Institute (United States)","awardRecipient":"Shaheen Sikandar"},{"awardId":"5T32GM133391","funderName":"National Institutes of Health (United States)","awardRecipient":"Isobel Fetter"},{"awardId":"EDUC4-12759","funderName":"California Institute for Regenerative Medicine (United States)","awardRecipient":"Isobel Fetter"}],"conflictsOfInterest":"The authors declare that there are no conflicts of interest present.
","dataTable":{"url":null},"extendedData":[],"funding":"","image":{"url":"https://portal.micropublication.org/uploads/49cde8b98d92c842d1d698171583afee.png"},"imageCaption":"(A) Schematic of aSTAT3 and shLMO2 expression in MDA-MB-468 cells followed by orthotopic transplant in NSG mice to evaluate tumor burden and metastasis. (B) Immunoblotting of MDA-MB-468 cells transduced with either control (pSicoR) or constitutively active STAT3 plasmid. (C) Tumor weight in control (pRSI12/pSicoR), shLMO2 (shLMO2/pSicoR), aSTAT3 (pRSI12/aSTAT3), and shLMO2/aSTAT3 tumors generated from MDA-MB-468 cell xenografts (n = 5 mice per group). (D) Representative fluorescent images of spontaneous RFP+/GFP+ lung metastases from mice with control, shLMO2, aSTAT3, and shLMO2/aSTAT3 tumors in (B). (E) Quantification of metastases in (D). Data shown as mean ± standard deviation. (F) Representative immunoblot of cytoplasmic and nuclear fractions of MDA-MB-468 cells transduced with control (pRSI12/pSicoR), shLMO2 (shLMO2/pSicoR), aSTAT3 (pRSI12/aSTAT3), and shLMO2/aSTAT3 plasmids, probed for phospho-STAT3 (Tyr705), STAT3, FLAG, Lamin B, and β-Tubulin 1. Densitometric values for each representative blot are below the respective band. (G) Quantification of cytoplasmic phosphor-STAT3 (Tyr705) as shown in (F), normalized to β-Tubulin 1 cytoplasmic loading control. (H) Quantification of nuclear phospho-STAT3 (Tyr705) as shown in (F), normalized to Lamin B nuclear loading control. For G-H, n = 5 biological replicates. (I) Quantification of cytoplasmic FLAG as shown in (F), normalized to β-Tubulin 1 cytoplasmic loading control. (J) Quantification of nuclear FLAG as shown in (F), normalized to Lamin B nuclear loading control. For I-J, n = 3 biological replicates. Statistical significance was calculated with ordinary 1-way ANOVA with multiple comparisons (C, E, G-H) and unpaired t-tests (I-J).
","imageTitle":"LMO2 regulates STAT3 localization to the nucleus in breast cancer cells
","methods":"Cell Line Generation
MDA-MB-468 and HEK293T cells were obtained from the American Type Culture Collection. Cells were cultured in DMEM supplemented with penicillin (120 μg/mL), streptomycin (100 μg/mL), amphotericin B (0.25 μg/mL), and 10% FBS. LMO2 shRNA targeting the 3′UTR (5′-GACGCATTTCGGTTGAGAA-3′) was cloned into the pRSI12-U6-(sh)-HTS4-UbiC-TagRFP-2A-Puro shRNA expression vector (Cellecta). The pRSI12 empty vector was used as a control. EF.STAT3C.Ubc.GFP was a gift from Linzhao Cheng (Addgene plasmid #24983; http://n2t.net/addgene:24983; RRID: Addgene_24983). pSicoR was a gift from Tyler Jacks (Addgene plasmid #11579; http://n2t.net/addgene:11579; RRID: Addgene_11579) and was used as an empty vector control for the aSTAT3 plasmid. Viruses were produced in HEK293T cells using the second-generation lentiviral system and transfection using Lipofectamine 2000 (Life Technologies). Supernatants were collected at 48 and 72 hours, filtered with a 0.45-μm filter, and precipitated with lentivirus precipitation solution (Alstem LLC) per the manufacturer’s instructions. Viral titers were determined by flow cytometry analyses of HEK293T cells infected with serial dilutions of concentrated virus.
Mouse Models
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) (stock #005557) mice were purchased from The Jackson Laboratory and bred at the University of California Santa Cruz (UCSC). All mice used for this study were maintained at the UCSC Animal Facility in accordance with the guidelines set forth by UCSC and the Institutional Animal Care and Use Committee (Protocol number SIKAS2010).
Xenografts
To prepare cells for orthotopic injection, cells were trypsinized with standard protocols, and live cell counts were assessed by Trypan Blue staining. Each cell line was resuspended in DMEM containing 40% Matrigel and subcutaneously injected into the fourth abdominal fat pads on one side of female NSG mice. 100,000 cells were used for each injection. Mice were monitored every week for tumor growth. All mice were euthanized if tumor growth reached the endpoint (1500 mm3). Tumor size was measured using digital calipers. Tumors were harvested and weighed, and lungs were harvested and placed in PBS on ice. The lungs were then imaged in brightfield, RFP, and GFP on a Keyence Biorevo BZ-9000 digital widefield microscope. The RFP and GFP channels were then merged with FIJI (Schindelin et al., 2012), and RFP/GFP double positive lung metastases were manually counted.
Subcellular fractionation
Whole cell lysates were generated by lysis with radioimmunoprecipitation assay (RIPA) buffer, along with protease and phosphatase inhibitor cocktails (Thermo Fisher Scientific). Subcellular fractionation was performed as described previously (Baghirova et al., 2015; Rubio et al., 2024). Briefly, cultured cells were washed with room temperature PBS before detachment with trypsin. Cells were resuspended in DMEM with 10% FBS and pelleted at 500 x g. Increasingly strong detergents were used to lyse the cells, and the cytoplasmic fraction, the membrane-bound organelle fraction, and finally the nuclear fraction were collected from the supernatant. After the supernatant was collected for each fraction, the remaining cell material was washed 3 times with the respective lysis buffer to remove any remaining protein before the next lysis step. Protein concentration was measured with the Pierce BCA Protein Assay Kit (Thermo Scientific).
Western Blotting
For each sample, 20 μg of protein lysate was added to 10 μL 4x NuPAGE LDS buffer with 4% β-mercaptoethanol, then boiled at 95°C for 5 minutes before gel electrophoresis. SDS-PAGE gels were run at 100 V for 70 min, then transferred onto polyvinylidene difluoride membranes (#IPFL00010, Millipore, Billerica, MA) at 70 V for 90 min. Membranes were blocked with 5% BSA/Tris-buffered saline–Tween 0.1% (TBST) for 1 hour at RT and then subsequently probed with primary antibodies diluted at 1:1000 in 5% BSA/Tris-buffered saline–Tween 0.1% (TBST) overnight at 4°C. Membranes were then incubated in secondary antibodies containing HRP for 1 hour at RT. Clarity Western ECL Substrate (Bio-Rad) was used to enable visualization on the Bio-Rad ChemiDoc. Washes in between incubations were done for 10 min × 3 using TBST.
Immunoblot Quantification
Western blot bands were quantified using FIJI (Schindelin et al., 2012) software and normalized to controls as indicated in the figure legend. Rectangular regions of interest were drawn over lanes, then the peaks were plotted using the “Plot Lanes” tool. Vertical lines were then drawn to define peaks of interest, then the wand tool was used to measure the size of each peak. Densitometric values for phospho-STAT3 were normalized to values for β-Tubulin 1, STAT3, or Lamin B as noted in figure legends. Each sample was normalized to the loading control in the same lane. For example, the cytoplasmic phospho-STAT3 value for the control condition was divided by the β-Tubulin 1 value for the control on the same gel.
Statistical Analysis
All graphs show the mean, and error bars indicate standard deviations. P values are calculated using ordinary 1-way ANOVA with multiple comparisons and unpaired t-tests with GraphPad Prism. For animal studies, sample size was not predetermined to ensure adequate power to detect a prespecified effect size, no animals were excluded from analyses, and investigators were not blinded to group allocation during experiments.
","reagents":"Cell Line | Genotype | Available From |
MDA-MB-468 | Homo sapiens, isolated from a pleural effusion of a female patient with metastatic adenocarcinoma of the breast | ATCC |
HEK293T | Homo sapiens, derived from embryonic kidney 293 cells, contains SV40 T-antigen | ATCC |
Plasmid | Description |
pSicoR | pSicoR was a gift from Tyler Jacks (Addgene plasmid #11579; http://n2t.net/addgene:11579; RRID: Addgene_11579) |
aSTAT3 | EF.STAT3C.Ubc.GFP was a gift from Linzhao Cheng (Addgene plasmid #24983; http://n2t.net/addgene:24983; RRID: Addgene_24983) |
pRSI12 | pRSI12-U6-(sh)-HTS4-UbiC-TagRFP-2A-Puro shRNA expression vector (Cellecta) |
shLMO2 | LMO2 shRNA targeting the 3′UTR (5′-GACGCATTTCGGTTGAGAA-3′) was cloned into the pRSI12 shRNA expression vector (Cellecta) |
Animal Strain | Genotype | Available From |
NSG Mus musculus | NOD.Cg-PrkdcscidIl2rgtm1Wjl/Szj | Jackson Laboratory (stock #005557) |
Antibody | Animal and Clonality | Immunogen | Concentration |
anti-FLAG | Rabbit polyclonal (Sigma-Aldrich #F7425) | DYKDDDDK | 1:2500 |
anti-STAT3 | Mouse monoclonal, clone 9D8 (Abcam #ab119352) | peptide within human STAT3 aa 650 to the C-terminus | 1:1000 |
anti-pSTAT3 (Y705) | Rabbit monoclonal, clone D3A7 (Cell Signaling Technology #9145) | synthetic phosphopeptide corresponding to residues surrounding Tyr705 of mouse Stat3 | 1:1000 |
anti-Lamin B | Goat polyclonal (Santa Cruz Biotechnology #sc-6216) | peptide mapping at the C-terminus of human Lamin B1 | 1:1000 |
anti-β-Tubulin 1 | Mouse monoclonal, clone SAP.4G5 (Sigma-Aldrich #T7816) | synthetic peptide corresponding to the C-terminal sequence of β-tubulin isotype I | 1:1000 |
anti-β-Actin, HRP conjugated | Mouse monoclonal, clone BA3R (Invitrogen #MA5-15739-HRP) | β-actin N-terminal peptide | 1:5000 |
anti-mouse IgG, HRP conjugated | Horse polyclonal (Cell Signaling Technology #7076) | mouse IgG heavy and light chain | 1:5000 |
anti-rabbit IgG, HRP conjugated | Goat polyclonal (Cell Signaling Technology #7074) | rabbit IgG heavy and light chain | 1:5000 |
anti-goat IgG, HRP conjugated | Donkey polyclonal (Jackson ImmunoResearch #705-035-147) | goat IgG heavy and light chain | 1:5000 |
Metastasis is the leading cause of breast cancer-related deaths, making it imperative to develop strategies to target metastasis (Dillekås et al., 2019; Siegel et al., 2025). It is well established that breast tumors contain heterogeneous populations, with only a small subset of tumor cells exhibiting tumor-initiating and metastatic capacity (Lawson et al., 2015; Celià-Terrassa and Kang, 2016; Sikandar et al., 2017). Understanding molecular mechanisms regulating metastasis-initiating cells (MICs) will broaden potential targets and treatment strategies for breast cancer.
Previous studies have demonstrated that inflammatory cytokines such as IL6 and TNFɑ activate the JAK/STAT and NFκB pathways, resulting in transcriptional changes leading to tumorigenesis and metastasis (Coussens and Werb, 2002; Quail and Joyce, 2013; Hibino et al., 2021). STAT3 is phosphorylated by JAK2, homodimerizes to move to the nucleus and regulate transcription of its target genes, promoting proliferation, survival, and self-renewal (Schindler and Jr, 1995).
We recently identified a population of MICs in breast cancer that express LMO2, a transcriptional adaptor protein in hematopoietic stem cells and a T-cell oncogene (Yamada et al., 1998; McCormack et al., 2010). Knocking down LMO2 did not affect the growth of primary tumors, but significantly reduced the number of circulating tumor cells and lung metastases (Sikandar et al., 2022). Mechanistically, we found that LMO2 binds to the transcription factor STAT3 and is required for STAT3 phosphorylation in breast cancer cells (Sikandar et al., 2022). Consistent with our previous findings, another study showed LMO2 activates STAT3 signaling in glioblastoma to increase stem-like activity of cancer cells, suggesting that LMO2 activates STAT3 signaling in multiple cancers (Park et al., 2022). Here, we further investigate interactions between LMO2 and STAT3 during breast cancer metastasis by combining constitutively activated STAT3 with the loss of LMO2.
STAT3 is constitutively activated in several cancers, including breast cancer (Kim et al., 2012; Carpenter and Lo, 2014; Galoczova et al., 2018; J.-H. Ma et al., 2020). Hence, we wanted to test whether activated STAT3 (aSTAT3) can rescue the effect of LMO2 knockdown. To test whether constitutively active STAT3 (aSTAT3) is sufficient to rescue the decreased metastatic potential observed upon LMO2 knockdown, we first obtained a FLAG-tagged aSTAT3 construct (Hillion et al., 2008) and confirmed its expression by immunoblotting (Fig. 1B). We then generated four cell lines combining LMO2 knockdown and aSTAT3 and their respective controls (Ventura et al., 2004). These cell lines were orthotopically transplanted into the mammary fat pad of female NSG mice, and tumor growth was monitored over time (Fig. 1A). We found that there is no difference in tumor growth between the control, shLMO2, aSTAT3, or aSTAT3/shLMO2 (Fig. 1C). This is consistent with our previous findings that LMO2 knockdown significantly reduced metastasis, but did not impact tumor growth (Sikandar et al., 2022). We also found that aSTAT3 did not increase the number of metastases (Fig. 1D-E). Importantly, mice with shLMO2/aSTAT3 tumors have reduced metastasis similar to the mice with LMO2 knockdown tumors, suggesting that the combination of constitutively active STAT3 and LMO2 knockdown is insufficient to rescue metastasis (Fig. 1D-E).
As LMO2 is an adaptor protein and facilitates the formation of transcription factor complexes (Yamada et al., 1998), we next wanted to understand whether LMO2 is required for STAT3 localization to the nucleus. Hence, we performed subcellular fractionation and immunoblotting to find that, as expected, pSTAT3 is primarily located in the nucleus in the control and aSTAT3 cell lines (Fig. 1F). We observed an increase in cytoplasmic pSTAT3 in the shLMO2/aSTAT3 cells compared to the control, suggesting that while the aSTAT3 construct increased pSTAT3, a significant amount of pSTAT3 remains in the cytoplasm and does not translocate to the nucleus. Indeed, in the nuclear fractions of both the shLMO2 and shLMO2/aSTAT3 conditions, there is a significant reduction in nuclear pSTAT3 compared to the control conditions (Fig. 1H). Because the aSTAT3 construct can dimerize in absence of phosphorylation and translocate to the nucleus (Hillion et al., 2008), we also probed for FLAG-tag to determine whether LMO2 modulates translocation of aSTAT3. While FLAG-tagged STAT3 is detected in both the cytoplasm and nucleus of aSTAT3 and shLMO2/aSTAT3 cells (Fig. 1F), the amount of aSTAT3 (as measured by FLAG expression) is significantly higher in the cytoplasm and reduced in the nucleus in shLMO2/aSTAT3 cells as compared to aSTAT3 control (Fig. 1I, J). This suggests that LMO2 regulates STAT3 nuclear localization, even when STAT3 is constitutively active. In summary, these data suggest a novel role for LMO2 in breast cancer cells; in addition to stabilizing JAK2-STAT3 interactions to promote phosphorylation (Sikandar et al., 2022), LMO2 actively facilitates STAT3 localization to the nucleus.
STAT3 phosphorylation and nuclear localization are associated with tumorigenesis and metastasis in multiple cancers, with increased nuclear STAT3 leading to reduced overall survival in patients (Huang et al., 2017; Chen et al., 2023; Zhang et al., 2024). STAT3 can localize to the nucleus without phosphorylation, but phosphorylation is required for STAT3’s transcription factor activity (Liu et al., 2005). We observed a significant reduction in nuclear pSTAT3 in shLMO2 and shLMO2/aSTAT3 conditions (Fig. 1H), suggesting that LMO2 promotes STAT3’s nuclear localization and thus its transcriptional activity. STAT3 is imported into the nucleus primarily through importin-ɑ3 (KPNA4) or importin-ɑ5 (KPNA1) in association with importin-β1 (KPNB1) (Liu et al., 2005; J. Ma and Cao, 2006). Some FLAG-tagged STAT3 is still found in the nucleus when LMO2 is knocked down but significantly reduced compared to control cells (Fig. 1J). Structurally, LMO2 is composed of 2 LIM fingers, each containing 2 zinc finger motifs (El Omari et al., 2011). Interestingly, other zinc finger-containing proteins such as EZI (Nakayama et al., 2002), ZBP-89 (Wu et al., 2004), KLF4 (Qin et al., 2013), and IKZF1 and IKZF3 (Read et al., 2017) have been shown to associate with and modulate nuclear localization of STAT3.
STAT3 signaling is an appealing target for treating cancer. Multiple STAT3 inhibitors have been investigated in clinical trials with various efficacies and tolerances (Hong et al., 2013; Ogura et al., 2015; Oh et al., 2015; Jonker et al., 2016; Tolcher et al., 2018; Feldman, 2024), but there are currently no FDA-approved therapies targeting STAT3. Inhibiting STAT3 signaling can lead to off-target toxicity, so targeting STAT3 only in cancer cells could improve outcomes. Since the oncogenic effects depend on STAT3’s nuclear localization, disrupting its nuclear import represents an alternative therapeutic strategy. Disruption of LMO2-STAT3 interactions using newly developed inhibitors for LMO2 could prevent nuclear accumulation and suppress STAT3-driven transcription (Milton-Harris et al., 2020; Bery et al., 2021). Therapeutically, this approach offers a potential strategy to selectively target constitutively active STAT3 in tumors while sparing transient STAT3 activation in normal tissues. However, it is also possible that LMO2 has additional functions independent of its interaction with STAT3 that contribute to metastasis. Future structure-function studies will determine how LMO2 promotes STAT3 localization to the nucleus in metastasis-initiating cells and whether LMO2 binds to additional molecules to modulate metastasis in breast cancer.
","references":[{"reference":"Sikandar SS, Kuo AH, Kalisky T, Cai S, Zabala M, Hsieh RW, et al., Clarke MF. 2017. Role of epithelial to mesenchymal transition associated genes in mammary gland regeneration and breast tumorigenesis. Nature Communications. 8: 1669.","pubmedId":"","doi":"10.1038/s41467-017-01666-2"},{"reference":"Dillekas H, Rogers MS, Straume O. 2019. Are 90% of deaths from cancer caused by metastases?. Cancer Medicine. 8: 5574.","pubmedId":"","doi":"10.1002/cam4.2474"},{"reference":"Yamada Y, Warren AJ, Dobson C, Forster A, Pannell R, Rabbitts TH. 1998. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proceedings of the National Academy of Sciences. 95: 3890.","pubmedId":"","doi":"10.1073/pnas.95.7.3890"},{"reference":"Mc Cormack MP, Young LF, Vasudevan S, De Graaf CA, Codrington R, Rabbitts TH, Jane SM, Curtis DJ. 2010. The Lmo2 Oncogene Initiates Leukemia in Mice by Inducing Thymocyte Self-Renewal. Science. 327: 879.","pubmedId":"","doi":"10.1126/science.1182378"},{"reference":"Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, Takai K, et al., Werb Z. 2015. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature. 526: 131.","pubmedId":"","doi":"10.1038/nature15260"},{"reference":"Celia Terrassa T, Kang Y. 2016. Distinctive properties of metastasis-initiating cells. Genes & Development. 30: 892.","pubmedId":"","doi":"10.1101/gad.277681.116"},{"reference":"Hibino S, Kawazoe T, Kasahara H, Itoh S, Ishimoto T, Sakata Yanagimoto M, Taniguchi K. 2021. Inflammation-Induced Tumorigenesis and Metastasis. International Journal of Molecular Sciences. 22: 5421.","pubmedId":"","doi":"10.3390/ijms22115421"},{"reference":"Coussens LM, Werb Z. 2002. Inflammation and cancer. Nature. 420: 860.","pubmedId":"","doi":"10.1038/nature01322"},{"reference":"Quail DF, Joyce JA. 2013. Microenvironmental regulation of tumor progression and metastasis. Nature Medicine. 19: 1423.","pubmedId":"","doi":"10.1038/nm.3394"},{"reference":"Hillion J, Dhara S, Sumter TF, Mukherjee M, Di Cello F, Belton A, et al., Resar LMS. 2008. The High-Mobility Group A1a/Signal Transducer and Activator of Transcription-3 Axis: An Achilles Heel for Hematopoietic Malignancies?. Cancer Research. 68: 10121.","pubmedId":"","doi":"10.1158/0008-5472.CAN-08-2121"},{"reference":"Galoczova M, Coates P, Vojtesek B. 2018. STAT3, stem cells, cancer stem cells and p63. Cellular & Molecular Biology Letters. 23: 12.","pubmedId":"","doi":"10.1186/s11658-018-0078-0"},{"reference":"Ma JH, Qin L, Li X. 2020. Role of STAT3 signaling pathway in breast cancer. Cell communication and signaling: CCS. 18: 33.","pubmedId":"","doi":"10.1186/s12964-020-0527-z"},{"reference":"Ventura A, Meissner A, Dillon CP, Mc Manus M, Sharp PA, Van Parijs L, Jaenisch R, Jacks T. 2004. Cre-lox-regulated conditional RNA interference from transgenes. Proceedings of the National Academy of Sciences. 101: 10380.","pubmedId":"","doi":"10.1073/pnas.0403954101"},{"reference":"Milton Harris L, Jeeves M, Walker SA, Ward SE, Mancini EJ. 2020. Small molecule inhibits T-cell acute lymphoblastic leukaemia oncogenic interaction through conformational modulation of LMO2. Oncotarget. 11: 1737.","pubmedId":"","doi":"10.18632/oncotarget.27580"},{"reference":"Kim SM, Kwon OJ, Hong YK, Kim JH, Solca F, Ha SJ, et al., Cho BC. 2012. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Molecular Cancer Therapeutics. 11: 2254.","pubmedId":"","doi":"10.1158/1535-7163.MCT-12-0311"},{"reference":"Carpenter RL, Lo HW. 2014. STAT3 Target Genes Relevant to Human Cancers. Cancers. 6: 897.","pubmedId":"","doi":"10.3390/cancers6020897"},{"reference":"Park CG, Choi SH, Lee SY, Eun K, Park MG, Jang J, et al., Kim H. 2022. Cytoplasmic LMO2-LDB1 Complex Activates STAT3 Signaling through Interaction with gp130-JAK in Glioma Stem Cells. Cells. 11: 2031.","pubmedId":"","doi":"10.3390/cells11132031"},{"reference":"Sikandar SS, Gulati GS, Antony J, Fetter I, Kuo AH, Ho WHD, et al., Clarke MF. 2022. Identification of a minority population of LMO2+ breast cancer cells that integrate into the vasculature and initiate metastasis. Science Advances. 8: eabm3548.","pubmedId":"","doi":"10.1126/sciadv.abm3548"},{"reference":"Bery N, Bataille CJR, Russell A, Hayes A, Raynaud F, Milhas S, et al., Rabbitts TH. 2021. A cell-based screening method using an intracellular antibody for discovering small molecules targeting the translocation protein LMO2. Science Advances. 7: eabg1950.","pubmedId":"","doi":"10.1126/sciadv.abg1950"},{"reference":"Ma J, Cao X. 2006. Regulation of Stat3 nuclear import by importin α5 and importin α7 via two different functional sequence elements. Cellular Signalling. 18: 1117.","pubmedId":"","doi":"10.1016/j.cellsig.2005.06.016"},{"reference":"Qin S, Zou Y, Zhang CL. 2013. Cross-talk between KLF4 and STAT3 regulates axon regeneration. Nature Communications. 4: 2633.","pubmedId":"","doi":"10.1038/ncomms3633"},{"reference":"Wu Y, Diab I, Zhang X, Izmailova ES, Zehner ZE. 2004. Stat3 enhances vimentin gene expression by binding to the antisilencer element and interacting with the repressor protein, ZBP-89. Oncogene. 23: 168.","pubmedId":"","doi":"10.1038/sj.onc.1207003"},{"reference":"Read KA, Powell MD, Baker CE, Sreekumar BK, Ringel Scaia VM, Bachus H, et al., Oestreich KJ. 2017. Integrated STAT3 and Ikaros Zinc Finger Transcription Factor Activities Regulate Bcl-6 Expression in CD4+ Th Cells. The Journal of Immunology. 199: 2377.","pubmedId":"","doi":"10.4049/jimmunol.1700106"},{"reference":"Nakayama K, Kim KW, Miyajima A. 2002. A novel nuclear zinc finger protein EZI enhances nuclear retention and transactivation of STAT3. The EMBO Journal. 21: 6174.","pubmedId":"","doi":"10.1093/emboj/cdf596"},{"reference":"El Omari K, Hoosdally SJ, Tuladhar K, Karia D, Vyas P, Patient R, Porcher C, Mancini EJ. 2011. Structure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complex. Blood. 117: 2146.","pubmedId":"","doi":"10.1182/blood-2010-07-293357"},{"reference":"Liu L, Mc Bride KM, Reich NC. 2005. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-α3. Proceedings of the National Academy of Sciences. 102: 8150.","pubmedId":"","doi":"10.1073/pnas.0501643102"},{"reference":"Zhang G, Chen X, Yu C, Cui L, Chen N, Yi G, et al., Zhou Y. 2024. FNIP1 suppresses colorectal cancer progression through inhibiting STAT3 phosphorylation and nuclear translocation. iScience. 27: 110730.","pubmedId":"","doi":"10.1016/j.isci.2024.110730"},{"reference":"Chen Q, Hu Q, Chen Y, Shen N, Zhang N, Li A, Li L, Li J. 2023. PRMT6 methylation of STAT3 regulates tumor metastasis in breast cancer. Cell Death & Disease. 14: 655.","pubmedId":"","doi":"10.1038/s41419-023-06148-6"},{"reference":"Huang Y, Wang J, Cao F, Jiang H, Li A, Li J, et al., Lu Y. 2017. SHP2 associates with nuclear localization of STAT3: significance in progression and prognosis of colorectal cancer. Scientific Reports. 7: 17597.","pubmedId":"","doi":"10.1038/s41598-017-17604-7"},{"reference":"Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, et al., O Callaghan CJ. 2016. A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): the CCTG/AGITG CO.23 trial. Annals of Oncology. 27: vi150.","pubmedId":"","doi":"10.1093/annonc/mdw370.03"},{"reference":"Tolcher A, Flaherty K, Shapiro GI, Berlin J, Witzig T, Habermann T, et al., Cote GM. 2018. A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers. The Oncologist. 23: 658.","pubmedId":"","doi":"10.1634/theoncologist.2017-0325"},{"reference":"Ogura M, Uchida T, Terui Y, Hayakawa F, Kobayashi Y, Taniwaki M, et al., Hatake K. 2015. Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. Cancer Science. 106: 896.","pubmedId":"","doi":"10.1111/cas.12683"},{"reference":"Oh DY, Lee SH, Han SW, Kim MJ, Kim TM, Kim TY, et al., Bang YJ. 2015. Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. Cancer Research and Treatment. 47: 607.","pubmedId":"","doi":"10.4143/crt.2014.249"},{"reference":"Feldman T. 2024. Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors. 66th ASH Annual Meeting","pubmedId":"","doi":""},{"reference":"Hong DS, Younes A, Fayad L, Fowler NH, Hagemeister FB, Mistry R, et al., Kurzrock R. 2013. A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers.. Journal of Clinical Oncology. 31: 8523.","pubmedId":"","doi":"10.1200/jco.2013.31.15_suppl.8523"},{"reference":"Schindler C, Jr JED. 1995. TRANSCRIPTIONAL RESPONSES TO POLYPEPTIDE LIGANDS: The JAK-STAT Pathway. Annual Review of Biochemistry. 64: 621.","pubmedId":"","doi":"10.1146/annurev.bi.64.070195.003201"},{"reference":"Rubio S, Molinuevo R, Sanz Gomez N, Zomorrodinia T, Cockrum CS, Luong E, et al., Hinck L. 2024. Nuclear VANGL2 Inhibits Lactogenic Differentiation. Cells. 13: 222.","pubmedId":"","doi":"10.3390/cells13030222"},{"reference":"Baghirova S, Hughes BG, Hendzel MJ, Schulz R. 2015. Sequential fractionation and isolation of subcellular proteins from tissue or cultured cells. MethodsX. 2: 440.","pubmedId":"","doi":"10.1016/j.mex.2015.11.001"},{"reference":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. 2025. Cancer statistics, 2025. CA: A Cancer Journal for Clinicians. 75: 10.","pubmedId":"","doi":"10.3322/caac.21871"},{"reference":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al., Cardona. 2012. Fiji: an open-source platform for biological-image analysis. Nature Methods 9: 676-682.
","pubmedId":"22743772","doi":" 10.1038/nmeth.2019"},{"reference":"Hillion J, Dhara S, Sumter TF, Mukherjee M, Di Cello F, Belton A, et al., Resar LM. 2008. The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies? Cancer Res 68(24): 10121-7.
","pubmedId":"19074878","doi":""}],"title":"LMO2 regulates STAT3 localization to the nucleus in breast cancer cells
","reviews":[],"curatorReviews":[]},{"id":"15190056-c73d-4eeb-8d50-a1ef678590ce","decision":"accept","abstract":"STAT3 phosphorylation and transcriptional activity promote breast cancer growth and metastasis. We have previously reported that the transcriptional adaptor LMO2 is required for metastasis in breast cancer and promotes STAT3-JAK2 interaction, leading to STAT3 phosphorylation in metastasis-initiating cells. Here, we find that constitutively activated STAT3 is insufficient to drive metastasis in the absence of LMO2. Mechanistically, we find that LMO2 is required not only for STAT3 phosphorylation in the cytoplasm but also for STAT3 translocation to the nucleus. These data suggest that LMO2 promotes STAT3 activation and localization to the nucleus in breast cancer cells.
","acknowledgements":"We thank Benjamin Abrams, UCSC Life Sciences Microscopy Center, RRID: SCR_021135 for technical support during image acquisition and processing.
","authors":[{"affiliations":["University of California, Santa Cruz","University of California, Santa Cruz"],"departments":["Molecular, Cell & Developmental Biology","Institute for the Biology of Stem Cells"],"credit":["dataCuration","investigation","methodology","visualization","writing_originalDraft","formalAnalysis","conceptualization"],"email":"ifetter@ucsc.edu","firstName":"Isobel J","lastName":"Fetter","submittingAuthor":false,"correspondingAuthor":false,"equalContribution":false,"WBId":null,"orcid":null},{"affiliations":["University of California, Santa Cruz"],"departments":["Molecular, Cell & Developmental Biology"],"credit":["dataCuration","investigation","methodology"],"email":"vharoaco@ucsc.edu","firstName":"Veronica","lastName":"Haro Acosta","submittingAuthor":false,"correspondingAuthor":false,"equalContribution":false,"WBId":null,"orcid":null},{"affiliations":["University of California, Santa Cruz"],"departments":["Molecular, Cell & Developmental Biology"],"credit":["investigation","methodology"],"email":"sparecadan@gmail.com","firstName":"Sachin ","lastName":"Parecadan","submittingAuthor":false,"correspondingAuthor":false,"equalContribution":false,"WBId":null,"orcid":null},{"affiliations":["University of California, Santa Cruz","University of California, Santa Cruz","University of California, Santa Cruz"],"departments":["Molecular, Cell & Developmental Biology","Institute for the Biology of Stem Cells","Genomics Institute",""],"credit":["conceptualization","formalAnalysis","fundingAcquisition","investigation","project","supervision","writing_originalDraft"],"email":"ssikanda@ucsc.edu","firstName":"Shaheen S","lastName":"Sikandar","submittingAuthor":true,"correspondingAuthor":true,"equalContribution":false,"WBId":null,"orcid":null}],"awards":[{"awardId":" R37CA269754","funderName":"National Cancer Institute (United States)","awardRecipient":"Shaheen Sikandar"},{"awardId":"5T32GM133391","funderName":"National Institutes of Health (United States)","awardRecipient":"Isobel Fetter"},{"awardId":"EDUC4-12759","funderName":"California Institute for Regenerative Medicine (United States)","awardRecipient":"Isobel Fetter"}],"conflictsOfInterest":"The authors declare that there are no conflicts of interest present.
","dataTable":{"url":null},"extendedData":[],"funding":"","image":{"url":"https://portal.micropublication.org/uploads/49cde8b98d92c842d1d698171583afee.png"},"imageCaption":"(A) Schematic of aSTAT3 and shLMO2 expression in MDA-MB-468 cells followed by orthotopic transplant in NSG mice to evaluate tumor burden and metastasis. (B) Immunoblotting of MDA-MB-468 cells transduced with either control (pSicoR) or constitutively active STAT3 plasmid. (C) Tumor weight in control (pRSI12/pSicoR), shLMO2 (shLMO2/pSicoR), aSTAT3 (pRSI12/aSTAT3), and shLMO2/aSTAT3 tumors generated from MDA-MB-468 cell xenografts (n = 5 mice per group). (D) Representative fluorescent images of spontaneous RFP+/GFP+ lung metastases from mice with control, shLMO2, aSTAT3, and shLMO2/aSTAT3 tumors in (B). (E) Quantification of metastases in (D). Data shown as mean ± standard deviation. (F) Representative immunoblot of cytoplasmic and nuclear fractions of MDA-MB-468 cells transduced with control (pRSI12/pSicoR), shLMO2 (shLMO2/pSicoR), aSTAT3 (pRSI12/aSTAT3), and shLMO2/aSTAT3 plasmids, probed for phospho-STAT3 (Tyr705), STAT3, FLAG, Lamin B, and β-Tubulin 1. Densitometric values for each representative blot are below the respective band. (G) Quantification of cytoplasmic phosphor-STAT3 (Tyr705) as shown in (F), normalized to β-Tubulin 1 cytoplasmic loading control. (H) Quantification of nuclear phospho-STAT3 (Tyr705) as shown in (F), normalized to Lamin B nuclear loading control. For G-H, n = 5 biological replicates. (I) Quantification of cytoplasmic FLAG as shown in (F), normalized to β-Tubulin 1 cytoplasmic loading control. (J) Quantification of nuclear FLAG as shown in (F), normalized to Lamin B nuclear loading control. For I-J, n = 3 biological replicates. Statistical significance was calculated with ordinary 1-way ANOVA with multiple comparisons (C, E, G-H) and unpaired t-tests (I-J).
","imageTitle":"LMO2 regulates STAT3 localization to the nucleus in breast cancer cells
","methods":"Cell Line Generation
MDA-MB-468 and HEK293T cells were obtained from the American Type Culture Collection. Cells were cultured in DMEM supplemented with penicillin (120 μg/mL), streptomycin (100 μg/mL), amphotericin B (0.25 μg/mL), and 10% FBS. LMO2 shRNA targeting the 3′UTR (5′-GACGCATTTCGGTTGAGAA-3′) was cloned into the pRSI12-U6-(sh)-HTS4-UbiC-TagRFP-2A-Puro shRNA expression vector (Cellecta). The pRSI12 empty vector was used as a control. EF.STAT3C.Ubc.GFP was a gift from Linzhao Cheng (Addgene plasmid #24983; http://n2t.net/addgene:24983; RRID: Addgene_24983). pSicoR was a gift from Tyler Jacks (Addgene plasmid #11579; http://n2t.net/addgene:11579; RRID: Addgene_11579) and was used as an empty vector control for the aSTAT3 plasmid. Viruses were produced in HEK293T cells using the second-generation lentiviral system and transfection using Lipofectamine 2000 (Life Technologies). Supernatants were collected at 48 and 72 hours, filtered with a 0.45-μm filter, and precipitated with lentivirus precipitation solution (Alstem LLC) per the manufacturer’s instructions. Viral titers were determined by flow cytometry analyses of HEK293T cells infected with serial dilutions of concentrated virus.
Mouse Models
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) (stock #005557) mice were purchased from The Jackson Laboratory and bred at the University of California Santa Cruz (UCSC). All mice used for this study were maintained at the UCSC Animal Facility in accordance with the guidelines set forth by UCSC and the Institutional Animal Care and Use Committee (Protocol number SIKAS2010).
Xenografts
To prepare cells for orthotopic injection, cells were trypsinized with standard protocols, and live cell counts were assessed by Trypan Blue staining. Each cell line was resuspended in DMEM containing 40% Matrigel and subcutaneously injected into the fourth abdominal fat pads on one side of female NSG mice. 100,000 cells were used for each injection. Mice were monitored every week for tumor growth. All mice were euthanized if tumor growth reached the endpoint (1500 mm3). Tumor size was measured using digital calipers. Tumors were harvested and weighed, and lungs were harvested and placed in PBS on ice. The lungs were then imaged in brightfield, RFP, and GFP on a Keyence Biorevo BZ-9000 digital widefield microscope. The RFP and GFP channels were then merged with FIJI (Schindelin et al., 2012), and RFP/GFP double positive lung metastases were manually counted.
Subcellular fractionation
Whole cell lysates were generated by lysis with radioimmunoprecipitation assay (RIPA) buffer, along with protease and phosphatase inhibitor cocktails (Thermo Fisher Scientific). Subcellular fractionation was performed as described previously (Baghirova et al., 2015; Rubio et al., 2024). Briefly, cultured cells were washed with room temperature PBS before detachment with trypsin. Cells were resuspended in DMEM with 10% FBS and pelleted at 500 x g. Increasingly strong detergents were used to lyse the cells, and the cytoplasmic fraction, the membrane-bound organelle fraction, and finally the nuclear fraction were collected from the supernatant. After the supernatant was collected for each fraction, the remaining cell material was washed 3 times with the respective lysis buffer to remove any remaining protein before the next lysis step. Protein concentration was measured with the Pierce BCA Protein Assay Kit (Thermo Scientific).
Western Blotting
For each sample, 20 μg of protein lysate was added to 10 μL 4x NuPAGE LDS buffer with 4% β-mercaptoethanol, then boiled at 95°C for 5 minutes before gel electrophoresis. SDS-PAGE gels were run at 100 V for 70 min, then transferred onto polyvinylidene difluoride membranes (#IPFL00010, Millipore, Billerica, MA) at 70 V for 90 min. Membranes were blocked with 5% BSA/Tris-buffered saline–Tween 0.1% (TBST) for 1 hour at RT and then subsequently probed with primary antibodies diluted at 1:1000 in 5% BSA/Tris-buffered saline–Tween 0.1% (TBST) overnight at 4°C. Membranes were then incubated in secondary antibodies containing HRP for 1 hour at RT. Clarity Western ECL Substrate (Bio-Rad) was used to enable visualization on the Bio-Rad ChemiDoc. Washes in between incubations were done for 10 min × 3 using TBST.
Immunoblot Quantification
Western blot bands were quantified using FIJI (Schindelin et al., 2012) software and normalized to controls as indicated in the figure legend. Rectangular regions of interest were drawn over lanes, then the peaks were plotted using the “Plot Lanes” tool. Vertical lines were then drawn to define peaks of interest, then the wand tool was used to measure the size of each peak. Densitometric values for phospho-STAT3 were normalized to values for β-Tubulin 1, STAT3, or Lamin B as noted in figure legends. Each sample was normalized to the loading control in the same lane. For example, the cytoplasmic phospho-STAT3 value for the control condition was divided by the β-Tubulin 1 value for the control on the same gel.
Statistical Analysis
All graphs show the mean, and error bars indicate standard deviations. P values are calculated using ordinary 1-way ANOVA with multiple comparisons and unpaired t-tests with GraphPad Prism. For animal studies, sample size was not predetermined to ensure adequate power to detect a prespecified effect size, no animals were excluded from analyses, and investigators were not blinded to group allocation during experiments.
","reagents":"Cell Line | Genotype | Available From |
MDA-MB-468 | Homo sapiens, isolated from a pleural effusion of a female patient with metastatic adenocarcinoma of the breast | ATCC |
HEK293T | Homo sapiens, derived from embryonic kidney 293 cells, contains SV40 T-antigen | ATCC |
Plasmid | Description |
pSicoR | pSicoR was a gift from Tyler Jacks (Addgene plasmid #11579; http://n2t.net/addgene:11579; RRID: Addgene_11579) |
aSTAT3 | EF.STAT3C.Ubc.GFP was a gift from Linzhao Cheng (Addgene plasmid #24983; http://n2t.net/addgene:24983; RRID: Addgene_24983) |
pRSI12 | pRSI12-U6-(sh)-HTS4-UbiC-TagRFP-2A-Puro shRNA expression vector (Cellecta) |
shLMO2 | LMO2 shRNA targeting the 3′UTR (5′-GACGCATTTCGGTTGAGAA-3′) was cloned into the pRSI12 shRNA expression vector (Cellecta) |
Animal Strain | Genotype | Available From |
NSG Mus musculus | NOD.Cg-PrkdcscidIl2rgtm1Wjl/Szj | Jackson Laboratory (stock #005557) |
Antibody | Animal and Clonality | Immunogen | Concentration |
anti-FLAG | Rabbit polyclonal (Sigma-Aldrich #F7425) | DYKDDDDK | 1:2500 |
anti-STAT3 | Mouse monoclonal, clone 9D8 (Abcam #ab119352) | peptide within human STAT3 aa 650 to the C-terminus | 1:1000 |
anti-pSTAT3 (Y705) | Rabbit monoclonal, clone D3A7 (Cell Signaling Technology #9145) | synthetic phosphopeptide corresponding to residues surrounding Tyr705 of mouse Stat3 | 1:1000 |
anti-Lamin B | Goat polyclonal (Santa Cruz Biotechnology #sc-6216) | peptide mapping at the C-terminus of human Lamin B1 | 1:1000 |
anti-β-Tubulin 1 | Mouse monoclonal, clone SAP.4G5 (Sigma-Aldrich #T7816) | synthetic peptide corresponding to the C-terminal sequence of β-tubulin isotype I | 1:1000 |
anti-β-Actin, HRP conjugated | Mouse monoclonal, clone BA3R (Invitrogen #MA5-15739-HRP) | β-actin N-terminal peptide | 1:5000 |
anti-mouse IgG, HRP conjugated | Horse polyclonal (Cell Signaling Technology #7076) | mouse IgG heavy and light chain | 1:5000 |
anti-rabbit IgG, HRP conjugated | Goat polyclonal (Cell Signaling Technology #7074) | rabbit IgG heavy and light chain | 1:5000 |
anti-goat IgG, HRP conjugated | Donkey polyclonal (Jackson ImmunoResearch #705-035-147) | goat IgG heavy and light chain | 1:5000 |
Metastasis is the leading cause of breast cancer-related deaths, making it imperative to develop strategies to target metastasis (Dillekås et al., 2019; Siegel et al., 2025). It is well established that breast tumors contain heterogeneous populations, with only a small subset of tumor cells exhibiting tumor-initiating and metastatic capacity (Lawson et al., 2015; Celià-Terrassa and Kang, 2016; Sikandar et al., 2017). Understanding molecular mechanisms regulating metastasis-initiating cells (MICs) will broaden potential targets and treatment strategies for breast cancer.
Previous studies have demonstrated that inflammatory cytokines such as IL6 and TNFɑ activate the JAK/STAT and NFκB pathways, resulting in transcriptional changes leading to tumorigenesis and metastasis (Coussens and Werb, 2002; Quail and Joyce, 2013; Hibino et al., 2021). STAT3 is phosphorylated by JAK2, homodimerizes to move to the nucleus and regulate transcription of its target genes, promoting proliferation, survival, and self-renewal (Schindler and Jr, 1995).
We recently identified a population of MICs in breast cancer that express LMO2, a transcriptional adaptor protein in hematopoietic stem cells and a T-cell oncogene (Yamada et al., 1998; McCormack et al., 2010). Knocking down LMO2 did not affect the growth of primary tumors, but significantly reduced the number of circulating tumor cells and lung metastases (Sikandar et al., 2022). Mechanistically, we found that LMO2 binds to the transcription factor STAT3 and is required for STAT3 phosphorylation in breast cancer cells (Sikandar et al., 2022). Consistent with our previous findings, another study showed LMO2 activates STAT3 signaling in glioblastoma to increase stem-like activity of cancer cells, suggesting that LMO2 activates STAT3 signaling in multiple cancers (Park et al., 2022). Here, we further investigate interactions between LMO2 and STAT3 during breast cancer metastasis by combining constitutively activated STAT3 with the loss of LMO2.
STAT3 is constitutively activated in several cancers, including breast cancer (Kim et al., 2012; Carpenter and Lo, 2014; Galoczova et al., 2018; J.-H. Ma et al., 2020). Hence, we wanted to test whether activated STAT3 (aSTAT3) can rescue the effect of LMO2 knockdown. To test whether constitutively active STAT3 (aSTAT3) is sufficient to rescue the decreased metastatic potential observed upon LMO2 knockdown, we first obtained a FLAG-tagged aSTAT3 construct (Hillion et al., 2008) and confirmed its expression by immunoblotting (Fig. 1B). We then generated four cell lines combining LMO2 knockdown and aSTAT3 and their respective controls (Ventura et al., 2004). These cell lines were orthotopically transplanted into the mammary fat pad of female NSG mice, and tumor growth was monitored over time (Fig. 1A). We found that there is no difference in tumor growth between the control, shLMO2, aSTAT3, or aSTAT3/shLMO2 (Fig. 1C). This is consistent with our previous findings that LMO2 knockdown significantly reduced metastasis, but did not impact tumor growth (Sikandar et al., 2022). We also found that aSTAT3 did not increase the number of metastases (Fig. 1D-E). Importantly, mice with shLMO2/aSTAT3 tumors have reduced metastasis similar to the mice with LMO2 knockdown tumors, suggesting that the combination of constitutively active STAT3 and LMO2 knockdown is insufficient to rescue metastasis (Fig. 1D-E).
As LMO2 is an adaptor protein and facilitates the formation of transcription factor complexes (Yamada et al., 1998), we next wanted to understand whether LMO2 is required for STAT3 localization to the nucleus. Hence, we performed subcellular fractionation and immunoblotting to find that, as expected, pSTAT3 is primarily located in the nucleus in the control and aSTAT3 cell lines (Fig. 1F). We observed an increase in cytoplasmic pSTAT3 in the shLMO2/aSTAT3 cells compared to the control, suggesting that while the aSTAT3 construct increased pSTAT3, a significant amount of pSTAT3 remains in the cytoplasm and does not translocate to the nucleus. Indeed, in the nuclear fractions of both the shLMO2 and shLMO2/aSTAT3 conditions, there is a significant reduction in nuclear pSTAT3 compared to the control conditions (Fig. 1H). Because the aSTAT3 construct can dimerize in absence of phosphorylation and translocate to the nucleus (Hillion et al., 2008), we also probed for FLAG-tag to determine whether LMO2 modulates translocation of aSTAT3. While FLAG-tagged STAT3 is detected in both the cytoplasm and nucleus of aSTAT3 and shLMO2/aSTAT3 cells (Fig. 1F), the amount of aSTAT3 (as measured by FLAG expression) is significantly higher in the cytoplasm and reduced in the nucleus in shLMO2/aSTAT3 cells as compared to aSTAT3 control (Fig. 1I, J). This suggests that LMO2 regulates STAT3 nuclear localization, even when STAT3 is constitutively active. In summary, these data suggest a novel role for LMO2 in breast cancer cells; in addition to stabilizing JAK2-STAT3 interactions to promote phosphorylation (Sikandar et al., 2022), LMO2 actively facilitates STAT3 localization to the nucleus.
STAT3 phosphorylation and nuclear localization are associated with tumorigenesis and metastasis in multiple cancers, with increased nuclear STAT3 leading to reduced overall survival in patients (Huang et al., 2017; Chen et al., 2023; Zhang et al., 2024). STAT3 can localize to the nucleus without phosphorylation, but phosphorylation is required for STAT3’s transcription factor activity (Liu et al., 2005). We observed a significant reduction in nuclear pSTAT3 in shLMO2 and shLMO2/aSTAT3 conditions (Fig. 1H), suggesting that LMO2 promotes STAT3’s nuclear localization and thus its transcriptional activity. STAT3 is imported into the nucleus primarily through importin-ɑ3 (KPNA4) or importin-ɑ5 (KPNA1) in association with importin-β1 (KPNB1) (Liu et al., 2005; J. Ma and Cao, 2006). Some FLAG-tagged STAT3 is still found in the nucleus when LMO2 is knocked down but significantly reduced compared to control cells (Fig. 1J). Structurally, LMO2 is composed of 2 LIM fingers, each containing 2 zinc finger motifs (El Omari et al., 2011). Interestingly, other zinc finger-containing proteins such as EZI (Nakayama et al., 2002), ZBP-89 (Wu et al., 2004), KLF4 (Qin et al., 2013), and IKZF1 and IKZF3 (Read et al., 2017) have been shown to associate with and modulate nuclear localization of STAT3.
STAT3 signaling is an appealing target for treating cancer. Multiple STAT3 inhibitors have been investigated in clinical trials with various efficacies and tolerances (Hong et al., 2013; Ogura et al., 2015; Oh et al., 2015; Jonker et al., 2016; Tolcher et al., 2018; Feldman, 2024), but there are currently no FDA-approved therapies targeting STAT3. Inhibiting STAT3 signaling can lead to off-target toxicity, so targeting STAT3 only in cancer cells could improve outcomes. Since the oncogenic effects depend on STAT3’s nuclear localization, disrupting its nuclear import represents an alternative therapeutic strategy. Disruption of LMO2-STAT3 interactions using newly developed inhibitors for LMO2 could prevent nuclear accumulation and suppress STAT3-driven transcription (Milton-Harris et al., 2020; Bery et al., 2021). Therapeutically, this approach offers a potential strategy to selectively target constitutively active STAT3 in tumors while sparing transient STAT3 activation in normal tissues. However, it is also possible that LMO2 has additional functions independent of its interaction with STAT3 that contribute to metastasis. Future structure-function studies will determine how LMO2 promotes STAT3 localization to the nucleus in metastasis-initiating cells and whether LMO2 binds to additional molecules to modulate metastasis in breast cancer.
","references":[{"reference":"Baghirova S, Hughes BG, Hendzel MJ, Schulz R. 2015. Sequential fractionation and isolation of subcellular proteins from tissue or cultured cells. MethodsX. 2: 440.","pubmedId":"","doi":"10.1016/j.mex.2015.11.001"},{"reference":"Bery N, Bataille CJR, Russell A, Hayes A, Raynaud F, Milhas S, et al., Rabbitts TH. 2021. A cell-based screening method using an intracellular antibody for discovering small molecules targeting the translocation protein LMO2. Science Advances. 7: eabg1950.","pubmedId":"","doi":"10.1126/sciadv.abg1950"},{"reference":"Carpenter RL, Lo HW. 2014. STAT3 Target Genes Relevant to Human Cancers. Cancers. 6: 897.","pubmedId":"","doi":"10.3390/cancers6020897"},{"reference":"Celia Terrassa T, Kang Y. 2016. Distinctive properties of metastasis-initiating cells. Genes & Development. 30: 892.","pubmedId":"","doi":"10.1101/gad.277681.116"},{"reference":"Chen Q, Hu Q, Chen Y, Shen N, Zhang N, Li A, Li L, Li J. 2023. PRMT6 methylation of STAT3 regulates tumor metastasis in breast cancer. Cell Death & Disease. 14: 655.","pubmedId":"","doi":"10.1038/s41419-023-06148-6"},{"reference":"Coussens LM, Werb Z. 2002. Inflammation and cancer. Nature. 420: 860.","pubmedId":"","doi":"10.1038/nature01322"},{"reference":"Dillekas H, Rogers MS, Straume O. 2019. Are 90% of deaths from cancer caused by metastases?. Cancer Medicine. 8: 5574.","pubmedId":"","doi":"10.1002/cam4.2474"},{"reference":"El Omari K, Hoosdally SJ, Tuladhar K, Karia D, Vyas P, Patient R, Porcher C, Mancini EJ. 2011. Structure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complex. Blood. 117: 2146.","pubmedId":"","doi":"10.1182/blood-2010-07-293357"},{"reference":"Feldman T. 2024. Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors. 66th ASH Annual Meeting","pubmedId":"","doi":""},{"reference":"Galoczova M, Coates P, Vojtesek B. 2018. STAT3, stem cells, cancer stem cells and p63. Cellular & Molecular Biology Letters. 23: 12.","pubmedId":"","doi":"10.1186/s11658-018-0078-0"},{"reference":"Hibino S, Kawazoe T, Kasahara H, Itoh S, Ishimoto T, Sakata Yanagimoto M, Taniguchi K. 2021. Inflammation-Induced Tumorigenesis and Metastasis. International Journal of Molecular Sciences. 22: 5421.","pubmedId":"","doi":"10.3390/ijms22115421"},{"reference":"Hillion J, Dhara S, Sumter TF, Mukherjee M, Di Cello F, Belton A, et al., Resar LMS. 2008. The High-Mobility Group A1a/Signal Transducer and Activator of Transcription-3 Axis: An Achilles Heel for Hematopoietic Malignancies?. Cancer Research. 68: 10121.","pubmedId":"","doi":"10.1158/0008-5472.CAN-08-2121"},{"reference":"Hillion J, Dhara S, Sumter TF, Mukherjee M, Di Cello F, Belton A, et al., Resar LM. 2008. The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies? Cancer Res 68(24): 10121-7.
","pubmedId":"19074878","doi":""},{"reference":"Hong DS, Younes A, Fayad L, Fowler NH, Hagemeister FB, Mistry R, et al., Kurzrock R. 2013. A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers.. Journal of Clinical Oncology. 31: 8523.","pubmedId":"","doi":"10.1200/jco.2013.31.15_suppl.8523"},{"reference":"Huang Y, Wang J, Cao F, Jiang H, Li A, Li J, et al., Lu Y. 2017. SHP2 associates with nuclear localization of STAT3: significance in progression and prognosis of colorectal cancer. Scientific Reports. 7: 17597.","pubmedId":"","doi":"10.1038/s41598-017-17604-7"},{"reference":"Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, et al., O Callaghan CJ. 2016. A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): the CCTG/AGITG CO.23 trial. Annals of Oncology. 27: vi150.","pubmedId":"","doi":"10.1093/annonc/mdw370.03"},{"reference":"Kim SM, Kwon OJ, Hong YK, Kim JH, Solca F, Ha SJ, et al., Cho BC. 2012. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Molecular Cancer Therapeutics. 11: 2254.","pubmedId":"","doi":"10.1158/1535-7163.MCT-12-0311"},{"reference":"Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, Takai K, et al., Werb Z. 2015. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature. 526: 131.","pubmedId":"","doi":"10.1038/nature15260"},{"reference":"Liu L, Mc Bride KM, Reich NC. 2005. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-α3. Proceedings of the National Academy of Sciences. 102: 8150.","pubmedId":"","doi":"10.1073/pnas.0501643102"},{"reference":"Ma J, Cao X. 2006. Regulation of Stat3 nuclear import by importin α5 and importin α7 via two different functional sequence elements. Cellular Signalling. 18: 1117.","pubmedId":"","doi":"10.1016/j.cellsig.2005.06.016"},{"reference":"Ma JH, Qin L, Li X. 2020. Role of STAT3 signaling pathway in breast cancer. Cell communication and signaling: CCS. 18: 33.","pubmedId":"","doi":"10.1186/s12964-020-0527-z"},{"reference":"Mc Cormack MP, Young LF, Vasudevan S, De Graaf CA, Codrington R, Rabbitts TH, Jane SM, Curtis DJ. 2010. The Lmo2 Oncogene Initiates Leukemia in Mice by Inducing Thymocyte Self-Renewal. Science. 327: 879.","pubmedId":"","doi":"10.1126/science.1182378"},{"reference":"Milton Harris L, Jeeves M, Walker SA, Ward SE, Mancini EJ. 2020. Small molecule inhibits T-cell acute lymphoblastic leukaemia oncogenic interaction through conformational modulation of LMO2. Oncotarget. 11: 1737.","pubmedId":"","doi":"10.18632/oncotarget.27580"},{"reference":"Nakayama K, Kim KW, Miyajima A. 2002. A novel nuclear zinc finger protein EZI enhances nuclear retention and transactivation of STAT3. The EMBO Journal. 21: 6174.","pubmedId":"","doi":"10.1093/emboj/cdf596"},{"reference":"Ogura M, Uchida T, Terui Y, Hayakawa F, Kobayashi Y, Taniwaki M, et al., Hatake K. 2015. Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. Cancer Science. 106: 896.","pubmedId":"","doi":"10.1111/cas.12683"},{"reference":"Oh DY, Lee SH, Han SW, Kim MJ, Kim TM, Kim TY, et al., Bang YJ. 2015. Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. Cancer Research and Treatment. 47: 607.","pubmedId":"","doi":"10.4143/crt.2014.249"},{"reference":"Park CG, Choi SH, Lee SY, Eun K, Park MG, Jang J, et al., Kim H. 2022. Cytoplasmic LMO2-LDB1 Complex Activates STAT3 Signaling through Interaction with gp130-JAK in Glioma Stem Cells. Cells. 11: 2031.","pubmedId":"","doi":"10.3390/cells11132031"},{"reference":"Qin S, Zou Y, Zhang CL. 2013. Cross-talk between KLF4 and STAT3 regulates axon regeneration. Nature Communications. 4: 2633.","pubmedId":"","doi":"10.1038/ncomms3633"},{"reference":"Quail DF, Joyce JA. 2013. Microenvironmental regulation of tumor progression and metastasis. Nature Medicine. 19: 1423.","pubmedId":"","doi":"10.1038/nm.3394"},{"reference":"Read KA, Powell MD, Baker CE, Sreekumar BK, Ringel Scaia VM, Bachus H, et al., Oestreich KJ. 2017. Integrated STAT3 and Ikaros Zinc Finger Transcription Factor Activities Regulate Bcl-6 Expression in CD4+ Th Cells. The Journal of Immunology. 199: 2377.","pubmedId":"","doi":"10.4049/jimmunol.1700106"},{"reference":"Rubio S, Molinuevo R, Sanz Gomez N, Zomorrodinia T, Cockrum CS, Luong E, et al., Hinck L. 2024. Nuclear VANGL2 Inhibits Lactogenic Differentiation. Cells. 13: 222.","pubmedId":"","doi":"10.3390/cells13030222"},{"reference":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al., Cardona. 2012. Fiji: an open-source platform for biological-image analysis. Nature Methods 9: 676-682.
","pubmedId":"22743772","doi":" 10.1038/nmeth.2019"},{"reference":"Schindler C, Jr JED. 1995. TRANSCRIPTIONAL RESPONSES TO POLYPEPTIDE LIGANDS: The JAK-STAT Pathway. Annual Review of Biochemistry. 64: 621.","pubmedId":"","doi":"10.1146/annurev.bi.64.070195.003201"},{"reference":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. 2025. Cancer statistics, 2025. CA: A Cancer Journal for Clinicians. 75: 10.","pubmedId":"","doi":"10.3322/caac.21871"},{"reference":"Sikandar SS, Gulati GS, Antony J, Fetter I, Kuo AH, Ho WHD, et al., Clarke MF. 2022. Identification of a minority population of LMO2+ breast cancer cells that integrate into the vasculature and initiate metastasis. Science Advances. 8: eabm3548.","pubmedId":"","doi":"10.1126/sciadv.abm3548"},{"reference":"Sikandar SS, Kuo AH, Kalisky T, Cai S, Zabala M, Hsieh RW, et al., Clarke MF. 2017. Role of epithelial to mesenchymal transition associated genes in mammary gland regeneration and breast tumorigenesis. Nature Communications. 8: 1669.","pubmedId":"","doi":"10.1038/s41467-017-01666-2"},{"reference":"Tolcher A, Flaherty K, Shapiro GI, Berlin J, Witzig T, Habermann T, et al., Cote GM. 2018. A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers. The Oncologist. 23: 658.","pubmedId":"","doi":"10.1634/theoncologist.2017-0325"},{"reference":"Ventura A, Meissner A, Dillon CP, Mc Manus M, Sharp PA, Van Parijs L, Jaenisch R, Jacks T. 2004. Cre-lox-regulated conditional RNA interference from transgenes. Proceedings of the National Academy of Sciences. 101: 10380.","pubmedId":"","doi":"10.1073/pnas.0403954101"},{"reference":"Wu Y, Diab I, Zhang X, Izmailova ES, Zehner ZE. 2004. Stat3 enhances vimentin gene expression by binding to the antisilencer element and interacting with the repressor protein, ZBP-89. Oncogene. 23: 168.","pubmedId":"","doi":"10.1038/sj.onc.1207003"},{"reference":"Yamada Y, Warren AJ, Dobson C, Forster A, Pannell R, Rabbitts TH. 1998. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proceedings of the National Academy of Sciences. 95: 3890.","pubmedId":"","doi":"10.1073/pnas.95.7.3890"},{"reference":"Zhang G, Chen X, Yu C, Cui L, Chen N, Yi G, et al., Zhou Y. 2024. FNIP1 suppresses colorectal cancer progression through inhibiting STAT3 phosphorylation and nuclear translocation. iScience. 27: 110730.","pubmedId":"","doi":"10.1016/j.isci.2024.110730"}],"title":"LMO2 regulates STAT3 localization to the nucleus in breast cancer cells
","reviews":[],"curatorReviews":[]},{"id":"e5e859be-db5c-4e57-93c9-5c2b3d8acab1","decision":"publish","abstract":"STAT3 phosphorylation and transcriptional activity promote breast cancer growth and metastasis. We have previously reported that the transcriptional adaptor LMO2 is required for metastasis in breast cancer and promotes STAT3-JAK2 interaction, leading to STAT3 phosphorylation in metastasis-initiating cells. Here, we find that constitutively activated STAT3 is insufficient to drive metastasis in the absence of LMO2. Mechanistically, we find that LMO2 is required not only for STAT3 phosphorylation in the cytoplasm but also for STAT3 translocation to the nucleus. These data suggest that LMO2 promotes STAT3 activation and localization to the nucleus in breast cancer cells.
","acknowledgements":"We thank Benjamin Abrams, UCSC Life Sciences Microscopy Center, RRID: SCR_021135 and Patricia Lovelace, UCSC flowcytometry core (RRID:SCR_021149). Purchase of the FACSDiscover S8 used in this research was made possible through the NIH grant 1S10OD036313-01.
","authors":[{"affiliations":["University of California, Santa Cruz","University of California, Santa Cruz"],"departments":["Molecular, Cell & Developmental Biology","Institute for the Biology of Stem Cells"],"credit":["dataCuration","investigation","methodology","visualization","writing_originalDraft","formalAnalysis","conceptualization"],"email":"ifetter@ucsc.edu","firstName":"Isobel J","lastName":"Fetter","submittingAuthor":false,"correspondingAuthor":false,"equalContribution":false,"WBId":null,"orcid":null},{"affiliations":["University of California, Santa Cruz"],"departments":["Molecular, Cell & Developmental Biology"],"credit":["dataCuration","investigation","methodology"],"email":"vharoaco@ucsc.edu","firstName":"Veronica","lastName":"Haro Acosta","submittingAuthor":false,"correspondingAuthor":false,"equalContribution":false,"WBId":null,"orcid":null},{"affiliations":["University of California, Santa Cruz"],"departments":["Molecular, Cell & Developmental Biology"],"credit":["investigation","methodology"],"email":"sparecadan@gmail.com","firstName":"Sachin ","lastName":"Parecadan","submittingAuthor":false,"correspondingAuthor":false,"equalContribution":false,"WBId":null,"orcid":null},{"affiliations":["University of California, Santa Cruz","University of California, Santa Cruz","University of California, Santa Cruz"],"departments":["Molecular, Cell & Developmental Biology","Institute for the Biology of Stem Cells","Genomics Institute",""],"credit":["conceptualization","formalAnalysis","fundingAcquisition","investigation","project","supervision","writing_originalDraft"],"email":"ssikanda@ucsc.edu","firstName":"Shaheen S","lastName":"Sikandar","submittingAuthor":true,"correspondingAuthor":true,"equalContribution":false,"WBId":null,"orcid":null}],"awards":[{"awardId":" R37CA269754","funderName":"National Cancer Institute (United States)","awardRecipient":"Shaheen Sikandar"},{"awardId":"5T32GM133391","funderName":"National Institutes of Health (United States)","awardRecipient":"Isobel Fetter"},{"awardId":"EDUC4-12759","funderName":"California Institute for Regenerative Medicine (United States)","awardRecipient":"Isobel Fetter"}],"conflictsOfInterest":"The authors declare that there are no conflicts of interest present.
","dataTable":{"url":null},"extendedData":[],"funding":"","image":{"url":"https://portal.micropublication.org/uploads/49cde8b98d92c842d1d698171583afee.png"},"imageCaption":"(A) Schematic of constitutively active STAT3 (aSTAT3) and shLMO2 expression in MDA-MB-468 cells followed by orthotopic transplant in NSG mice to evaluate tumor burden and metastasis. (B) Immunoblotting of MDA-MB-468 cells transduced with either control (pSicoR) or aSTAT3 plasmid. (C) Tumor weight in control (pRSI12/pSicoR), shLMO2 (shLMO2/pSicoR), aSTAT3 (pRSI12/aSTAT3), and shLMO2/aSTAT3 tumors generated from MDA-MB-468 cell xenografts. (D) Representative fluorescent images of spontaneous RFP+/GFP+ lung metastases from mice with control, shLMO2, aSTAT3, and shLMO2/aSTAT3 tumors in (B). (E) Quantification of metastases in (D). For C-E, n = 5 mice per group. (F) Representative immunoblot of cytoplasmic and nuclear fractions of MDA-MB-468 cells transduced with control (pRSI12/pSicoR), shLMO2 (shLMO2/pSicoR), aSTAT3 (pRSI12/aSTAT3), and shLMO2/aSTAT3 plasmids, probed for phospho-STAT3 (Tyr705), STAT3, FLAG, Lamin B, and β-Tubulin 1. Densitometric values for each representative blot are below the respective band. (G) Quantification of cytoplasmic phospho-STAT3 (Tyr705) as shown in (F), normalized to β-Tubulin 1 cytoplasmic loading control. (H) Quantification of nuclear phospho-STAT3 (Tyr705) as shown in (F), normalized to Lamin B nuclear loading control. For G-H, n = 5 biological replicates. (I) Quantification of cytoplasmic FLAG as shown in (F), normalized to β-Tubulin 1 cytoplasmic loading control. (J) Quantification of nuclear FLAG as shown in (F), normalized to Lamin B nuclear loading control. For I-J, n = 3 biological replicates. Data shown as mean ± standard deviation. Statistical significance was calculated with ordinary 1-way ANOVA with multiple comparisons (C, E, G-H) and unpaired t-tests (I-J).
","imageTitle":"LMO2 regulates STAT3 localization to the nucleus in breast cancer cells
","methods":"Cell Line Generation
MDA-MB-468 and HEK293T cells were obtained from the American Type Culture Collection. Cells were cultured in DMEM supplemented with penicillin (120 μg/mL), streptomycin (100 μg/mL), amphotericin B (0.25 μg/mL), and 10% FBS. LMO2 shRNA targeting the 3′UTR (5′-GACGCATTTCGGTTGAGAA-3′) was cloned into the pRSI12-U6-(sh)-HTS4-UbiC-TagRFP-2A-Puro shRNA expression vector (Cellecta). The pRSI12 empty vector was used as a control. EF.STAT3C.Ubc.GFP was a gift from Linzhao Cheng (Addgene plasmid #24983; http://n2t.net/addgene:24983; RRID: Addgene_24983). pSicoR was a gift from Tyler Jacks (Addgene plasmid #11579; http://n2t.net/addgene:11579; RRID: Addgene_11579) and was used as an empty vector control for the aSTAT3 plasmid. Viruses were produced in HEK293T cells using the second-generation lentiviral system and transfection using Lipofectamine 2000 (Life Technologies). Supernatants were collected at 48 and 72 hours, filtered with a 0.45-μm filter, and precipitated with lentivirus precipitation solution (Alstem LLC) per the manufacturer’s instructions. Viral titers were determined by flow cytometry analyses of HEK293T cells infected with serial dilutions of concentrated virus.
Mouse Models
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) (stock #005557) mice were purchased from The Jackson Laboratory and bred at the University of California Santa Cruz (UCSC). All mice used for this study were maintained at the UCSC Animal Facility in accordance with the guidelines set forth by UCSC and the Institutional Animal Care and Use Committee (Protocol number SIKAS2010).
Xenografts
To prepare cells for orthotopic injection, cells were trypsinized with standard protocols, and live cell counts were assessed by Trypan Blue staining. Each cell line was resuspended in DMEM containing 40% Matrigel and subcutaneously injected into the fourth abdominal fat pads on one side of female NSG mice. 100,000 cells were used for each injection. Mice were monitored every week for tumor growth. All mice were euthanized if tumor growth reached the endpoint (1500 mm3). Tumor size was measured using digital calipers. Tumors were harvested and weighed, and lungs were harvested and placed in PBS on ice. The lungs were then imaged in brightfield, RFP, and GFP on a Keyence Biorevo BZ-9000 digital widefield microscope. The RFP and GFP channels were then merged with FIJI (Schindelin et al., 2012), and RFP/GFP double positive lung metastases were manually counted.
Subcellular fractionation
Whole cell lysates were generated by lysis with radioimmunoprecipitation assay (RIPA) buffer, along with protease and phosphatase inhibitor cocktails (Thermo Fisher Scientific). Subcellular fractionation was performed as described previously (Baghirova et al., 2015; Rubio et al., 2024). Briefly, cultured cells were washed with room temperature PBS before detachment with trypsin. Cells were resuspended in DMEM with 10% FBS and pelleted at 500 x g. Increasingly strong detergents were used to lyse the cells, and the cytoplasmic fraction, the membrane-bound organelle fraction, and finally the nuclear fraction were collected from the supernatant. After the supernatant was collected for each fraction, the remaining cell material was washed 3 times with the respective lysis buffer to remove any remaining protein before the next lysis step. Protein concentration was measured with the Pierce BCA Protein Assay Kit (Thermo Scientific).
Western Blotting
For each sample, 20 μg of protein lysate was added to 10 μL 4x NuPAGE LDS buffer with 4% β-mercaptoethanol, then boiled at 95°C for 5 minutes before gel electrophoresis. SDS-PAGE gels were run at 100 V for 70 min, then transferred onto polyvinylidene difluoride membranes (Millipore) at 70 V for 90 min. Membranes were blocked with 5% BSA/Tris-buffered saline–Tween 0.1% (TBST) for 1 hour at RT and then subsequently probed with primary antibodies diluted at 1:1000 in 5% BSA/Tris-buffered saline–Tween 0.1% (TBST) overnight at 4°C. Membranes were then incubated in secondary antibodies containing HRP for 1 hour at RT. Clarity Western ECL Substrate (Bio-Rad) was used to enable visualization on the Bio-Rad ChemiDoc. Washes in between incubations were done for 10 min × 3 using TBST.
Immunoblot Quantification
Western blot bands were quantified using FIJI (Schindelin et al., 2012) software and normalized to controls as indicated in the figure legend. Rectangular regions of interest were drawn over lanes, then the peaks were plotted using the “Plot Lanes” tool. Vertical lines were then drawn to define peaks of interest, then the wand tool was used to measure the size of each peak. Densitometric values for phospho-STAT3 and FLAG were normalized to values for β-Tubulin 1, or Lamin B as noted in figure legends. Each sample was normalized to the loading control in the same lane. For example, the cytoplasmic phospho-STAT3 value for the control condition was divided by the β-Tubulin 1 value for the control on the same gel.
Statistical Analysis
All graphs show the mean, and error bars indicate standard deviations. P values are calculated using ordinary 1-way ANOVA with multiple comparisons and unpaired t-tests with GraphPad Prism. For animal studies, sample size was not predetermined to ensure adequate power to detect a prespecified effect size, no animals were excluded from analyses, and investigators were not blinded to group allocation during experiments.
","reagents":"Cell Line | Genotype | Available From |
MDA-MB-468 | Homo sapiens, isolated from a pleural effusion of a female patient with metastatic adenocarcinoma of the breast | ATCC |
HEK293T | Homo sapiens, derived from embryonic kidney 293 cells, contains SV40 T-antigen | ATCC |
Plasmid | Description |
pSicoR | pSicoR was a gift from Tyler Jacks (Addgene plasmid #11579; http://n2t.net/addgene:11579; RRID: Addgene_11579) |
aSTAT3 | EF.STAT3C.Ubc.GFP was a gift from Linzhao Cheng (Addgene plasmid #24983; http://n2t.net/addgene:24983; RRID: Addgene_24983) |
pRSI12 | pRSI12-U6-(sh)-HTS4-UbiC-TagRFP-2A-Puro shRNA expression vector (Cellecta) |
shLMO2 | LMO2 shRNA targeting the 3′UTR (5′-GACGCATTTCGGTTGAGAA-3′) was cloned into the pRSI12 shRNA expression vector (Cellecta) |
Animal Strain | Genotype | Available From |
NSG Mus musculus | NOD.Cg-PrkdcscidIl2rgtm1Wjl/Szj | Jackson Laboratory (stock #005557) |
Antibody | Animal and Clonality | Immunogen | Concentration |
anti-FLAG | Rabbit polyclonal (Sigma-Aldrich #F7425) | DYKDDDDK | 1:2500 |
anti-STAT3 | Mouse monoclonal, clone 9D8 (Abcam #ab119352) | peptide within human STAT3 aa 650 to the C-terminus | 1:1000 |
anti-pSTAT3 (Y705) | Rabbit monoclonal, clone D3A7 (Cell Signaling Technology #9145) | synthetic phosphopeptide corresponding to residues surrounding Tyr705 of mouse Stat3 | 1:1000 |
anti-Lamin B | Goat polyclonal (Santa Cruz Biotechnology #sc-6216) | peptide mapping at the C-terminus of human Lamin B1 | 1:1000 |
anti-β-Tubulin 1 | Mouse monoclonal, clone SAP.4G5 (Sigma-Aldrich #T7816) | synthetic peptide corresponding to the C-terminal sequence of β-tubulin isotype I | 1:1000 |
anti-β-Actin, HRP conjugated | Mouse monoclonal, clone BA3R (Invitrogen #MA5-15739-HRP) | β-actin N-terminal peptide | 1:5000 |
anti-mouse IgG, HRP conjugated | Horse polyclonal (Cell Signaling Technology #7076) | mouse IgG heavy and light chain | 1:5000 |
anti-rabbit IgG, HRP conjugated | Goat polyclonal (Cell Signaling Technology #7074) | rabbit IgG heavy and light chain | 1:5000 |
anti-goat IgG, HRP conjugated | Donkey polyclonal (Jackson ImmunoResearch #705-035-147) | goat IgG heavy and light chain | 1:5000 |
Metastasis is the leading cause of breast cancer-related deaths, making it imperative to develop strategies to target metastasis (Dillekås et al., 2019; Siegel et al., 2025). It is well established that breast tumors contain heterogeneous populations, with only a small subset of tumor cells exhibiting tumor-initiating and metastatic capacity (Lawson et al., 2015; Celià-Terrassa and Kang, 2016; Sikandar et al., 2017). Understanding molecular mechanisms regulating metastasis-initiating cells (MICs) will broaden potential targets and treatment strategies for breast cancer.
Previous studies have demonstrated that inflammatory cytokines such as IL6 and TNFα activate the JAK/STAT and NFκB pathways, resulting in transcriptional changes leading to tumorigenesis and metastasis (Coussens and Werb, 2002; Quail and Joyce, 2013; Hibino et al., 2021). STAT3 is phosphorylated by JAK2, homodimerizes to move to the nucleus and regulate transcription of its target genes, promoting proliferation, survival, and self-renewal (Schindler and Darnell, 1995).
We recently identified a population of MICs in breast cancer that express LMO2, a transcriptional adaptor protein in hematopoietic stem cells and a T-cell oncogene (Yamada et al., 1998; McCormack et al., 2010). LMO2 knockdown did not affect the growth of primary tumors, but significantly reduced the number of circulating tumor cells and lung metastases (Sikandar et al., 2022). Mechanistically, we found that LMO2 binds to the transcription factor STAT3 and is required for STAT3 phosphorylation in breast cancer cells (Sikandar et al., 2022). Consistent with our previous findings, another study showed LMO2 activates STAT3 signaling in glioblastoma to increase stem-like activity of cancer cells, suggesting that LMO2 activates STAT3 signaling in multiple cancers (Park et al., 2022). Here, we further investigate interactions between LMO2 and STAT3 during breast cancer metastasis by combining constitutively activated STAT3 with the loss of LMO2.
STAT3 is constitutively activated in several cancers, including breast cancer (Kim et al., 2012; Carpenter and Lo, 2014; Galoczova et al., 2018; J.-H. Ma et al., 2020). To test whether constitutively active STAT3 (aSTAT3) is sufficient to rescue the decreased metastatic potential observed upon LMO2 knockdown, we first obtained a FLAG-tagged aSTAT3 construct (Hillion et al., 2008) and confirmed its expression by immunoblotting (Fig. 1B). We then generated four cell lines combining LMO2 knockdown and aSTAT3 and their respective controls (Ventura et al., 2004). These cell lines were orthotopically transplanted into the mammary fat pad of female NSG mice, and tumor growth was monitored over time (Fig. 1A). We found that there is no difference in tumor growth among the control, shLMO2, aSTAT3, and aSTAT3/shLMO2 (Fig. 1C). This is consistent with our previous findings that LMO2 knockdown significantly reduced metastasis, but did not impact tumor growth (Sikandar et al., 2022). We also found that aSTAT3 did not increase the number of metastases (Fig. 1D-E). Importantly, mice with shLMO2/aSTAT3 tumors have reduced metastasis similar to the mice with LMO2 knockdown tumors, suggesting that the combination of constitutively active STAT3 and LMO2 knockdown is insufficient to rescue metastasis (Fig. 1D-E).
As LMO2 is an adaptor protein and facilitates the formation of transcription factor complexes (Yamada et al., 1998), we next wanted to understand whether LMO2 is required for STAT3 localization to the nucleus. Hence, we performed subcellular fractionation and immunoblotting to find that, as expected, pSTAT3 is primarily located in the nucleus in the control and aSTAT3 cell lines (Fig. 1F). We observed an increase in cytoplasmic pSTAT3 in the shLMO2/aSTAT3 cells compared to the control, suggesting that while the aSTAT3 construct increased pSTAT3, a significant amount of pSTAT3 remains in the cytoplasm and does not translocate to the nucleus (Fig. 1G). Indeed, in the nuclear fractions of both the shLMO2 and shLMO2/aSTAT3 conditions, there is a significant reduction in nuclear pSTAT3 compared to the control conditions (Fig. 1H). Because the aSTAT3 construct can dimerize in absence of phosphorylation and translocate to the nucleus (Hillion et al., 2008), we also probed for FLAG-tag to determine whether LMO2 modulates translocation of aSTAT3. While FLAG-tagged STAT3 is detected in both the cytoplasm and nucleus of aSTAT3 and shLMO2/aSTAT3 cells (Fig. 1F), the amount of aSTAT3 (as measured by FLAG expression) is significantly higher in the cytoplasm and reduced in the nucleus in shLMO2/aSTAT3 cells as compared to aSTAT3 control (Fig. 1I, J). This suggests that LMO2 regulates STAT3 nuclear localization, even when STAT3 is constitutively active. In summary, these data suggest a novel role for LMO2 in breast cancer cells; in addition to stabilizing JAK2-STAT3 interactions to promote phosphorylation (Sikandar et al., 2022), LMO2 actively facilitates STAT3 localization to the nucleus.
STAT3 phosphorylation and nuclear localization are associated with tumorigenesis and metastasis in multiple cancers, with increased nuclear STAT3 leading to reduced overall survival in patients (Huang et al., 2017; Chen et al., 2023; Zhang et al., 2024). STAT3 can localize to the nucleus without phosphorylation, but phosphorylation is required for STAT3’s transcription factor activity (Liu et al., 2005). We observed a significant reduction in nuclear pSTAT3 in shLMO2 and shLMO2/aSTAT3 conditions (Fig. 1H), suggesting that LMO2 promotes STAT3’s nuclear localization and thus its transcriptional activity. STAT3 is imported into the nucleus primarily through importin-α3 (KPNA4) or importin-α5 (KPNA1) in association with importin-β1 (KPNB1) (Liu et al., 2005; J. Ma and Cao, 2006). Some FLAG-tagged STAT3 is still found in the nucleus when LMO2 is knocked down but significantly reduced compared to control cells (Fig. 1J). Structurally, LMO2 is composed of 2 LIM fingers, each containing 2 zinc finger motifs (El Omari et al., 2011). Interestingly, other zinc finger-containing proteins such as EZI (Nakayama et al., 2002), ZBP-89 (Wu et al., 2004), KLF4 (Qin et al., 2013), and IKZF1 and IKZF3 (Read et al., 2017) have been shown to associate with and modulate nuclear localization of STAT3.
STAT3 signaling is an appealing target for treating cancer. Multiple STAT3 inhibitors have been investigated in clinical trials with various efficacies and tolerances (Hong et al., 2013; Ogura et al., 2015; Oh et al., 2015; Jonker et al., 2016; Tolcher et al., 2018; Feldman, 2024), but there are currently no FDA-approved therapies targeting STAT3. Inhibiting STAT3 signaling can lead to off-target toxicity, so targeting STAT3 only in cancer cells could improve outcomes. Since the oncogenic effects depend on STAT3’s nuclear localization, disrupting its nuclear import represents an alternative therapeutic strategy. Disruption of LMO2-STAT3 interactions using newly developed inhibitors for LMO2 could prevent nuclear accumulation and suppress STAT3-driven transcription (Milton-Harris et al., 2020; Bery et al., 2021). Therapeutically, this approach offers a potential strategy to selectively target constitutively active STAT3 in tumors while sparing transient STAT3 activation in normal tissues. However, it is also possible that LMO2 has additional functions independent of its interaction with STAT3 that contribute to metastasis. Future structure-function studies will determine how LMO2 promotes STAT3 localization to the nucleus in metastasis-initiating cells and whether LMO2 binds to additional molecules to modulate metastasis in breast cancer.
","references":[{"reference":"Baghirova S, Hughes BG, Hendzel MJ, Schulz R. 2015. Sequential fractionation and isolation of subcellular proteins from tissue or cultured cells. MethodsX. 2: 440.","pubmedId":"","doi":"10.1016/j.mex.2015.11.001"},{"reference":"Bery N, Bataille CJR, Russell A, Hayes A, Raynaud F, Milhas S, et al., Rabbitts TH. 2021. A cell-based screening method using an intracellular antibody for discovering small molecules targeting the translocation protein LMO2. Science Advances. 7: eabg1950.","pubmedId":"","doi":"10.1126/sciadv.abg1950"},{"reference":"Carpenter RL, Lo HW. 2014. STAT3 Target Genes Relevant to Human Cancers. Cancers. 6: 897.","pubmedId":"","doi":"10.3390/cancers6020897"},{"reference":"Celia Terrassa T, Kang Y. 2016. Distinctive properties of metastasis-initiating cells. Genes & Development. 30: 892.","pubmedId":"","doi":"10.1101/gad.277681.116"},{"reference":"Chen Q, Hu Q, Chen Y, Shen N, Zhang N, Li A, Li L, Li J. 2023. PRMT6 methylation of STAT3 regulates tumor metastasis in breast cancer. Cell Death & Disease. 14: 655.","pubmedId":"","doi":"10.1038/s41419-023-06148-6"},{"reference":"Coussens LM, Werb Z. 2002. Inflammation and cancer. Nature. 420: 860.","pubmedId":"","doi":"10.1038/nature01322"},{"reference":"Dillekas H, Rogers MS, Straume O. 2019. Are 90% of deaths from cancer caused by metastases?. Cancer Medicine. 8: 5574.","pubmedId":"","doi":"10.1002/cam4.2474"},{"reference":"El Omari K, Hoosdally SJ, Tuladhar K, Karia D, Vyas P, Patient R, Porcher C, Mancini EJ. 2011. Structure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complex. Blood. 117: 2146.","pubmedId":"","doi":"10.1182/blood-2010-07-293357"},{"reference":"Feldman T. 2024. Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors. 66th ASH Annual Meeting","pubmedId":"","doi":""},{"reference":"Galoczova M, Coates P, Vojtesek B. 2018. STAT3, stem cells, cancer stem cells and p63. Cellular & Molecular Biology Letters. 23: 12.","pubmedId":"","doi":"10.1186/s11658-018-0078-0"},{"reference":"Hibino S, Kawazoe T, Kasahara H, Itoh S, Ishimoto T, Sakata Yanagimoto M, Taniguchi K. 2021. Inflammation-Induced Tumorigenesis and Metastasis. International Journal of Molecular Sciences. 22: 5421.","pubmedId":"","doi":"10.3390/ijms22115421"},{"reference":"Hillion J, Dhara S, Sumter TF, Mukherjee M, Di Cello F, Belton A, et al., Resar LMS. 2008. The High-Mobility Group A1a/Signal Transducer and Activator of Transcription-3 Axis: An Achilles Heel for Hematopoietic Malignancies?. Cancer Research. 68: 10121.","pubmedId":"","doi":"10.1158/0008-5472.CAN-08-2121"},{"reference":"Hillion J, Dhara S, Sumter TF, Mukherjee M, Di Cello F, Belton A, et al., Resar LM. 2008. The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies? Cancer Res 68(24): 10121-7.
","pubmedId":"19074878","doi":""},{"reference":"Hong DS, Younes A, Fayad L, Fowler NH, Hagemeister FB, Mistry R, et al., Kurzrock R. 2013. A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers.. Journal of Clinical Oncology. 31: 8523.","pubmedId":"","doi":"10.1200/jco.2013.31.15_suppl.8523"},{"reference":"Huang Y, Wang J, Cao F, Jiang H, Li A, Li J, et al., Lu Y. 2017. SHP2 associates with nuclear localization of STAT3: significance in progression and prognosis of colorectal cancer. Scientific Reports. 7: 17597.","pubmedId":"","doi":"10.1038/s41598-017-17604-7"},{"reference":"Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, et al., O Callaghan CJ. 2016. A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): the CCTG/AGITG CO.23 trial. Annals of Oncology. 27: vi150.","pubmedId":"","doi":"10.1093/annonc/mdw370.03"},{"reference":"Kim SM, Kwon OJ, Hong YK, Kim JH, Solca F, Ha SJ, et al., Cho BC. 2012. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Molecular Cancer Therapeutics. 11: 2254.","pubmedId":"","doi":"10.1158/1535-7163.MCT-12-0311"},{"reference":"Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, Takai K, et al., Werb Z. 2015. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature. 526: 131.","pubmedId":"","doi":"10.1038/nature15260"},{"reference":"Liu L, Mc Bride KM, Reich NC. 2005. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-α3. Proceedings of the National Academy of Sciences. 102: 8150.","pubmedId":"","doi":"10.1073/pnas.0501643102"},{"reference":"Ma J, Cao X. 2006. Regulation of Stat3 nuclear import by importin α5 and importin α7 via two different functional sequence elements. Cellular Signalling. 18: 1117.","pubmedId":"","doi":"10.1016/j.cellsig.2005.06.016"},{"reference":"Ma JH, Qin L, Li X. 2020. Role of STAT3 signaling pathway in breast cancer. Cell communication and signaling: CCS. 18: 33.","pubmedId":"","doi":"10.1186/s12964-020-0527-z"},{"reference":"Mc Cormack MP, Young LF, Vasudevan S, De Graaf CA, Codrington R, Rabbitts TH, Jane SM, Curtis DJ. 2010. The Lmo2 Oncogene Initiates Leukemia in Mice by Inducing Thymocyte Self-Renewal. Science. 327: 879.","pubmedId":"","doi":"10.1126/science.1182378"},{"reference":"Milton Harris L, Jeeves M, Walker SA, Ward SE, Mancini EJ. 2020. Small molecule inhibits T-cell acute lymphoblastic leukaemia oncogenic interaction through conformational modulation of LMO2. Oncotarget. 11: 1737.","pubmedId":"","doi":"10.18632/oncotarget.27580"},{"reference":"Nakayama K, Kim KW, Miyajima A. 2002. A novel nuclear zinc finger protein EZI enhances nuclear retention and transactivation of STAT3. The EMBO Journal. 21: 6174.","pubmedId":"","doi":"10.1093/emboj/cdf596"},{"reference":"Ogura M, Uchida T, Terui Y, Hayakawa F, Kobayashi Y, Taniwaki M, et al., Hatake K. 2015. Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies. Cancer Science. 106: 896.","pubmedId":"","doi":"10.1111/cas.12683"},{"reference":"Oh DY, Lee SH, Han SW, Kim MJ, Kim TM, Kim TY, et al., Bang YJ. 2015. Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. Cancer Research and Treatment. 47: 607.","pubmedId":"","doi":"10.4143/crt.2014.249"},{"reference":"Park CG, Choi SH, Lee SY, Eun K, Park MG, Jang J, et al., Kim H. 2022. Cytoplasmic LMO2-LDB1 Complex Activates STAT3 Signaling through Interaction with gp130-JAK in Glioma Stem Cells. Cells. 11: 2031.","pubmedId":"","doi":"10.3390/cells11132031"},{"reference":"Qin S, Zou Y, Zhang CL. 2013. Cross-talk between KLF4 and STAT3 regulates axon regeneration. Nature Communications. 4: 2633.","pubmedId":"","doi":"10.1038/ncomms3633"},{"reference":"Quail DF, Joyce JA. 2013. Microenvironmental regulation of tumor progression and metastasis. Nature Medicine. 19: 1423.","pubmedId":"","doi":"10.1038/nm.3394"},{"reference":"Read KA, Powell MD, Baker CE, Sreekumar BK, Ringel Scaia VM, Bachus H, et al., Oestreich KJ. 2017. Integrated STAT3 and Ikaros Zinc Finger Transcription Factor Activities Regulate Bcl-6 Expression in CD4+ Th Cells. The Journal of Immunology. 199: 2377.","pubmedId":"","doi":"10.4049/jimmunol.1700106"},{"reference":"Rubio S, Molinuevo R, Sanz Gomez N, Zomorrodinia T, Cockrum CS, Luong E, et al., Hinck L. 2024. Nuclear VANGL2 Inhibits Lactogenic Differentiation. Cells. 13: 222.","pubmedId":"","doi":"10.3390/cells13030222"},{"reference":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al., Cardona. 2012. Fiji: an open-source platform for biological-image analysis. Nature Methods 9: 676-682.
","pubmedId":"22743772","doi":" 10.1038/nmeth.2019"},{"reference":"Schindler C, Jr JED. 1995. TRANSCRIPTIONAL RESPONSES TO POLYPEPTIDE LIGANDS: The JAK-STAT Pathway. Annual Review of Biochemistry. 64: 621.","pubmedId":"","doi":"10.1146/annurev.bi.64.070195.003201"},{"reference":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. 2025. Cancer statistics, 2025. CA: A Cancer Journal for Clinicians. 75: 10.","pubmedId":"","doi":"10.3322/caac.21871"},{"reference":"Sikandar SS, Gulati GS, Antony J, Fetter I, Kuo AH, Ho WHD, et al., Clarke MF. 2022. Identification of a minority population of LMO2+ breast cancer cells that integrate into the vasculature and initiate metastasis. Science Advances. 8: eabm3548.","pubmedId":"","doi":"10.1126/sciadv.abm3548"},{"reference":"Sikandar SS, Kuo AH, Kalisky T, Cai S, Zabala M, Hsieh RW, et al., Clarke MF. 2017. Role of epithelial to mesenchymal transition associated genes in mammary gland regeneration and breast tumorigenesis. Nature Communications. 8: 1669.","pubmedId":"","doi":"10.1038/s41467-017-01666-2"},{"reference":"Tolcher A, Flaherty K, Shapiro GI, Berlin J, Witzig T, Habermann T, et al., Cote GM. 2018. A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers. The Oncologist. 23: 658.","pubmedId":"","doi":"10.1634/theoncologist.2017-0325"},{"reference":"Ventura A, Meissner A, Dillon CP, Mc Manus M, Sharp PA, Van Parijs L, Jaenisch R, Jacks T. 2004. Cre-lox-regulated conditional RNA interference from transgenes. Proceedings of the National Academy of Sciences. 101: 10380.","pubmedId":"","doi":"10.1073/pnas.0403954101"},{"reference":"Wu Y, Diab I, Zhang X, Izmailova ES, Zehner ZE. 2004. Stat3 enhances vimentin gene expression by binding to the antisilencer element and interacting with the repressor protein, ZBP-89. Oncogene. 23: 168.","pubmedId":"","doi":"10.1038/sj.onc.1207003"},{"reference":"Yamada Y, Warren AJ, Dobson C, Forster A, Pannell R, Rabbitts TH. 1998. The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proceedings of the National Academy of Sciences. 95: 3890.","pubmedId":"","doi":"10.1073/pnas.95.7.3890"},{"reference":"Zhang G, Chen X, Yu C, Cui L, Chen N, Yi G, et al., Zhou Y. 2024. FNIP1 suppresses colorectal cancer progression through inhibiting STAT3 phosphorylation and nuclear translocation. iScience. 27: 110730.","pubmedId":"","doi":"10.1016/j.isci.2024.110730"}],"title":"LMO2 regulates STAT3 localization to the nucleus in breast cancer cells
","reviews":[],"curatorReviews":[]}]}},"species":{"species":[{"value":"acer saccharum","label":"Acer saccharum","imageSrc":"","imageAlt":"","mod":"TreeGenes","modLink":"https://treegenesdb.org","linkVariable":""},{"value":"achillea millefolium","label":"Achillea millefolium","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"acinetobacter baylyi","label":"Acinetobacter baylyi","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"actinobacteria bacterium","label":"Actinobacteria bacterium","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"adelges tsugae","label":"Adelges tsugae","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"adenocaulon chilense","label":"Adenocaulon chilense","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"aedes japonicus","label":"Aedes japonicus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"aegorhinus vitulus","label":"Aegorhinus vitulus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"alaimidae","label":"Alaimidae","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"allobates femoralis","label":"Allobates femoralis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"alnus glutinosa","label":"Alnus glutinosa","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"alosa aestivalis","label":"Alosa aestivalis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"alosa pseudoharengus","label":"Alosa pseudoharengus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"alternaria alternata","label":"Alternaria alternata","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"amynthas agrestis","label":"Amynthas Agrestis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"ancylostoma caninum","label":"Ancylostoma caninum","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"ancylostoma ceylanicum","label":"Ancylostoma ceylanicum","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"anemone multifida","label":"Anemone multifida","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"anguilla rostrata","label":"Anguilla rostrata","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"anisakis simplex","label":"Anisakis simplex","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"anomala albopilosa","label":"Anomala albopilosa","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"anthomyiidae sp","label":"Anthomyiidae sp","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"anthomyiidae sp","label":"Anthomyiidae sp","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"arabidopsis","label":"Arabidopsis","imageSrc":"arabidopsis.png","imageAlt":"Arabidopsis graphic by Zoe Zorn CC BY 4.0","mod":"TAIR","modLink":"https://arabidopsis.org","linkVariable":""},{"value":"architeuthis dux","label":"Architeuthis dux","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"arion vulgaris","label":"Arion vulgaris","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"armeria","label":"Armeria","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"artemia","label":"Artemia","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"arthrobacter sp.","label":"Arthrobacter sp.","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"ascaridia","label":"Ascaridia","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"ascaridia galli","label":"Ascaridia galli","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"asparagopsis taxiformis","label":"Asparagopsis taxiformis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"astatotilapia burtoni","label":"Astatotilapia burtoni","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"avena sativa","label":"Avena sativa","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"aves","label":"Aves","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"bacillus","label":"Bacillus (firmicutes)","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"bacillus cereus","label":"Bacillus cereus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"bacillus mycoides","label":"Bacillus mycoides","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"bacillus subtilis","label":"Bacillus subtilis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"bacillus thuringiensis","label":"Bacillus thuringiensis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"bacillus toyonensis","label":"Bacillus toyonensis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"bacillus wiedmannii","label":"Bacillus wiedmannii","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"bacteria","label":"Bacteria","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"bacteriophage","label":"Bacteriophage","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"bactrocera","label":"Bactrocera sp.","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"batrachospermum gelatinosum","label":"Batrachospermum gelatinosum","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"betula lenta","label":"Betula lenta","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"betula nigra","label":"Betula nigra","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"bombus dahlbohmii","label":"Bombus dahlbohmii","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"bombus terrestris","label":"Bombus terrestris","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"bombyx mori","label":"Bombyx mori","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"bos taurus","label":"Bos Taurus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"brachygobius doriae","label":"Brachygobius doriae","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"brassica oleracea","label":"Brassica oleracea","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"brassica rapa","label":"Brassica rapa","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"brugia malayi","label":"Brugia malayi","imageSrc":"","imageAlt":"","mod":"WormBase","modLink":"www.wormbase.org","linkVariable":""},{"value":"burkholderia thailandensis","label":"Burkholderia thailandensis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"buttiauxella","label":"Buttiauxella","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"caenorhabditis brenneri","label":"Caenorhabditis brenneri","imageSrc":"","imageAlt":"","mod":"WormBase","modLink":"www.wormbase.org","linkVariable":""},{"value":"caenorhabditis briggsae","label":"Caenorhabditis briggsae","imageSrc":"","imageAlt":"","mod":"WormBase","modLink":"www.wormbase.org","linkVariable":""},{"value":"c. elegans","label":"Caenorhabditis elegans","imageSrc":"c-elegans.jpg","imageAlt":"C. elegans graphic by Zoe Zorn CC BY 4.0","mod":"WormBase","modLink":"https://wormbase.org","linkVariable":""},{"value":"caenorhabditis inopinata","label":"Caenorhabditis inopinata","imageSrc":"","imageAlt":"","mod":"WormBase","modLink":"www.wormbase.org","linkVariable":""},{"value":"caenorhabditis japonica","label":"Caenorhabditis japonica","imageSrc":"","imageAlt":"","mod":"WormBase","modLink":"www.wormbase.org","linkVariable":""},{"value":"caenorhabditis nigoni","label":"Caenorhabditis nigoni","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"caenorhabditis remanei","label":"Caenorhabditis remanei","imageSrc":"","imageAlt":"","mod":"WormBase","modLink":"www.wormbase.org","linkVariable":""},{"value":"caenorhabditis tropicalis","label":"Caenorhabditis tropicalis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"calidifontibacillus","label":"Calidifontibacillus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"calidifontibacillus erzuremensis","label":"Calidifontibacillus erzuremensis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"calliphora sp","label":"Calliphora sp","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"caltha sagittata","label":"Caltha sagittata","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"cambarus latimanus","label":"Cambarus latimanus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"candida albicans","label":"Candida albicans","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"canis familiaris","label":"Canis familiaris","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"cannabis sativa","label":"Cannabis sativa","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"caretta caretta","label":"Caretta caretta","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"cassiopea xamachana","label":"Cassiopea xamachana","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"caulobacter vibrioides","label":"Caulobacter vibrioides","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"cephalopods","label":"Cephalopoda","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"cerastium arvense","label":"Cerastium arvense","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"ceriodaphnia","label":"Ceriodaphnia","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"ceroglossus suturalis","label":"Ceroglossus suturalis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"chaetoceros","label":"Chaetoceros","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"chamaecrista fasciculata","label":"Chamaecrista fasciculata","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"chilicola chalcidiformis","label":"Chilicola chalcidiformis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"chitinimonas","label":"Chitinimonas","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"chlamydomonas reinhardtii","label":"Chlamydomonas reinhardtii","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"chromobacterium","label":"Chromobacterium","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"chrysemys picta","label":"Chrysemys picta","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"chrysoperla rufilabris","label":"Chrysoperla rufilabris","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"citrus","label":"Citrus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"clavibacter sp.","label":"Clavibacter sp.","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"colinus virginianus","label":"Colinus virginianus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"crassostrea virginica","label":"Crassostrea virginica","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"crithidia fasciculata","label":"Crithidia fasciculata","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"cutibacterium acnes","label":"Cutibacterium acnes","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"cyanobacteria","label":"Cyanobacteria","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"daphnia","label":"Daphnia","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"daphnia pulex","label":"Daphnia pulex","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"diabrotica virgifera","label":"Diabrotica virgifera","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"diabrotica virgifera virgifera virus 1","label":"Diabrotica virgifera virgifera virus 1","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"d. discoideum","label":"Dictyostelium discoideum","imageSrc":"dicty.png","imageAlt":"D. discoideum","mod":"dictyBase","modLink":"http://dictybase.org","linkVariable":""},{"value":"diptera","label":"Diptera","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"dotocryptus bellicosus","label":"Dotocryptus bellicosus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"drechmeria coniospora","label":"Drechmeria coniospora","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"drosophila","label":"Drosophila","imageSrc":"drosophila.png","imageAlt":"Drosophila graphic by Zoe Zorn CC BY 4.0","mod":"FlyBase","modLink":"https://flybase.org/doi/","linkVariable":"doi"},{"value":"dryopteris campyloptera","label":"Dryopteris campyloptera","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"dryopteris expansa","label":"Dryopteris expansa","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"dryopteris intermedia","label":"Dryopteris intermedia","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"dugesia dorotocephala","label":"Dugesia dorotocephala","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"elasmobranchii","label":"Elasmobranchii","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"embryophyta","label":"Embryophyta","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"enoploteuthis chunii","label":"Enoploteuthis chunii","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"enterobacter aerogenes","label":"Enterobacter aerogenes","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"enterococcus raffinosus","label":"Enterococcus raffinosus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"epichloë coenophiala","label":"Epichloë coenophiala","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"equus caballus","label":"Equus caballus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"erigeron sp","label":"Erigeron sp","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"eristalis","label":"Eristalis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"eruca vesicaria","label":"Eruca vesicaria","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"erwinia carotovora","label":"Erwinia carotovora","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"erythronium americanum","label":"Erythronium americanum","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"escherichia coli","label":"Escherichia coli","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"eukaryota","label":"Eukaryotes","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"felis catus","label":"Felis catus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"francisella novicida","label":"Francisella novicida","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"francisella tularensis","label":"Francisella tularensis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"fraxinus americana","label":"Fraxinus americana","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"fucus distichus","label":"Fucus distichus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"fungi","label":"Fungi","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"gasteropelecus sp.","label":"Gasteropelecus sp.","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"geranium sp","label":"Geranium sp","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"girardia","label":"Girardia","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"glaucomys volans","label":"Glaucomys volans","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"glycine max","label":"Glycine max","imageSrc":"","imageAlt":"","mod":"Soybase","modLink":"https://soybase.org","linkVariable":""},{"value":"glyptemys insculpta","label":"Glyptemys insculpta","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"gossypium hirsutum","label":"Gossypium hirsutum","imageSrc":"","imageAlt":"","mod":"CottonGen","modLink":"https://www.cottongen.org/","linkVariable":""},{"value":"gromphadorhina portentosa","label":"Gromphadorhina portentosa","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"gryllodes sigillatus","label":"Gryllodes sigillatus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"haliotis rufescens","label":"Haliotis rufescens","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"hepacivirus hominis","label":"Hepatitis C Virus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"herpes simplex virus type 1","label":"Herpes simplex virus type 1","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"human","label":"Human","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"human coronavirus oc43","label":"Human coronavirus OC43","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"hydra vulgaris","label":"Hydra vulgaris","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"hydropsyche sp","label":"Hydropsyche sp","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"hymenoptera","label":"Hymenoptera","imageSrc":"","imageAlt":"","mod":"Hymenoptera Genome Database","modLink":"https://hymenoptera.elsiklab.missouri.edu/","linkVariable":""},{"value":"hypochaeris radicata","label":"Hypochaeris radicata","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"hypodynerus vespiformis","label":"Hypodynerus vespiformis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"iflaviridae","label":"Iflaviridae","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"iflavuris","label":"Iflavirus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"ipomoea hederacea","label":"Ipomoea hederacea","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"ischnomera","label":"Ischnomera","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"ischnomera ruficollis","label":"Ischnomera ruficollis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"julidochromis marlieri","label":"Julidochromis marlieri","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"juniperus virginiana","label":"Juniperus virginiana","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"kluyveromyces marxianus","label":"Kluyveromyces marxianus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"l. casei","label":"L. casei","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"lacticaseibacillus casei","label":"Lacticaseibacillus casei","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"larentiinae sp","label":"Larentiinae sp","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"laurus nobilis","label":"Laurus nobilis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"lepidoptera","label":"Lepidoptera","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"leucanthemum vulgare","label":"Leucanthemum vulgare","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"linepithema humile","label":"Linepithema humile","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"liometopum occidentale","label":"Liometopum occidentale","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"lolium arundinaceum","label":"Lolium arundinaceum","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"lontra longicaudis","label":"Lontra longicaudis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"lumbriculus variegatus","label":"Lumbriculus variegatus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"lumbricus terrestris","label":"Lumbricus terrestris","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"lupinus polyphyllus","label":"Lupinus polyphyllus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"lycorma delicatula","label":"Lycorma delicatula","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"lynx rufus","label":"Lynx rufus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"magnaporthe oryzae","label":"Magnaporthe oryzae","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"mammalia","label":"Mammalia","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"manihot esculenta","label":"Manihot esculenta","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"medicago lupulina","label":"Medicago lupulina","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"meloidogyne","label":"Meloidogyne","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"mimus polyglottos","label":"Mimus polyglottos","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"bryophyta","label":"Mosses","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"mouse","label":"Mouse","imageSrc":"","imageAlt":"","mod":"MGI","modLink":"https://informatics.jax.org","linkVariable":""},{"value":"m. minutoides","label":"Mus minutoides","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"mycobacterium smegmatis","label":"Mycobacterium smegmatis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"nakaseomyces glabratus","label":"Nakaseomyces glabratus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"nauphoeta cinerea","label":"Nauphoeta cinerea","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"neurospora","label":"Neurospora","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"n. benthamiana","label":"Nicotiana benthamiana","imageSrc":"","imageAlt":"","mod":"Solgenomics Network","modLink":"https://solgenomics.net/organism/Nicotiana_benthamiana/genome","linkVariable":""},{"value":"nicotiana tabacum","label":"Nicotiana tabacum","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"noctuidae","label":"Noctuidae","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"noctuidae sp","label":"Noctuidae sp","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"nothobranchius furzeri","label":"Nothobranchius furzeri","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"onchocerca volvulus","label":"Onchocerca volvulus","imageSrc":"","imageAlt":"","mod":"WormBase","modLink":"www.wormbase.org","linkVariable":""},{"value":"orconectes virilis","label":"Orconectes virilis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"ormia ochracea","label":"Ormia ochracea","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"o. sativa","label":"Oryza sativa","imageSrc":"","imageAlt":"","mod":"Gramene","modLink":"https://www.gramene.org/","linkVariable":""},{"value":"other","label":"Other","imageSrc":"","imageAlt":"","mod":null,"modLink":null,"linkVariable":null},{"value":"oxalis enneaphylla","label":"Oxalis enneaphylla","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"paenarthrobacter nicotinovorans","label":"Paenarthrobacter nicotinovorans","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"paenarthrobacter nicotinovorans","label":"Paenarthrobacter nicotinovorans","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"pantoea","label":"Pantoea","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"pantoea agglomerans","label":"Pantoea agglomerans","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"papaver sp","label":"Papaver sp","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"paramecium bursaria","label":"Paramecium bursaria","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"partitiviridae","label":"Partitiviridae","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"pelodiscus sinensis","label":"Pelodiscus sinensis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"perezia recurvata","label":"Perezia recurvata","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"petromyzon marinus","label":"Petromyzon marinus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"photinus pyralis","label":"Photinus pyralis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"photinus pyralis associated partiti-like virus","label":"Photinus pyralis associated partiti-like virus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"photinus pyralis iflavirus 1","label":"Photinus pyralis iflavirus 1","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"physcomitrium patens","label":"Physcomitrium patens","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"pinus strobus","label":"Pinus strobus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"pinus taeda","label":"Pinus taeda","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"platycheirus","label":"Platycheirus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"plectus sambesii","label":"Plectus sambesii","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"pogonomyrmex occidentalis","label":"Pogonomyrmex occidentalis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"poncirus trifoliata","label":"Poncirus trifoliata","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"populus deltoides","label":"Populus deltoides","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"potato virus y","label":"Potato virus Y","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"primula magellanica","label":"Primula magellanica","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"pristionchus pacificus","label":"Pristionchus pacificus","imageSrc":"","imageAlt":"","mod":"WormBase","modLink":"www.wormbase.org","linkVariable":""},{"value":"prunus persica","label":"Prunus persica","imageSrc":"","imageAlt":"","mod":"Genome Database for Rosaceae","modLink":"https://www.rosaceae.org/","linkVariable":""},{"value":"psalmopoeus iriminia","label":"Psalmopoeus iriminia","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"pseudanabaena sp.","label":"Pseudanabaena sp.","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"pseudomonas","label":"Pseudomonas","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"pseudomonas aeruginosa","label":"Pseudomonas aeruginosa","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"pseudomonas glycinae","label":"Pseudomonas glycinae","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"pseudomonas putida","label":"Pseudomonas putida","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"pseudomonas syringae","label":"Pseudomonas syringae","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"pterophyllum scalare","label":"Pterophyllum scalare","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"python regius","label":"Python regius","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"quercus macrocarpa","label":"Quercus macrocarpa","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"ralstonia solanacearum","label":"Ralstonia solanacearum","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"ranitomeya imitator","label":"Ranitomeya imitator","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"ranunculus peduncularis","label":"Ranunculus peduncularis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"rat","label":"Rat","imageSrc":"","imageAlt":"","mod":"RGD","modLink":"https://rgd.mcw.edu","linkVariable":""},{"value":"rheinheimera","label":"Rheinheimera","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"ribes rubrum","label":"Ribes rubrum","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"sars-cov-2","label":"SARS-CoV-2","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"s. cerevisiae","label":"Saccharomyces cerevisiae","imageSrc":"yeast.png","imageAlt":"Yeast graphic by Zoe Zorn CC BY 4.0","mod":"SGD","modLink":"https://yeastgenome.org","linkVariable":""},{"value":"saccharomyces paradoxus","label":"Saccharomyces paradoxus ","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"s. uvarum","label":"Saccharomyces uvarum","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"schistosoma","label":"Schistosoma","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"schizosaccharomyces japonicus","label":"Schizosaccharomyces japonicus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"s. pombe","label":"Schizosaccharomyces pombe","imageSrc":"pombe.png","imageAlt":"Pombe graphic by Zoe Zorn © Caltech","mod":"PomBase","modLink":"https://www.pombase.org/reference/PMID:","linkVariable":"pmId"},{"value":"schmidtea mediterranea","label":"Schmidtea mediterranea","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"senecio sp","label":"Senecio sp","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"simocephalus","label":"Simocephalus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"siraitia grosvenorii","label":"Siraitia grosvenorii","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"solanum lycopersicum","label":"Solanum lycopersicum","imageSrc":"","imageAlt":"","mod":"Solgenomics Network","modLink":"https://solgenomics.net/organism/1/view/","linkVariable":""},{"value":"sorghum","label":"Sorghum","imageSrc":"","imageAlt":"","mod":"SorghumBase","modLink":"https://www.sorghumbase.org","linkVariable":""},{"value":"spiroplasma eriocheiris","label":"Spiroplasma eriocheiris","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"staphylococcus aureus","label":"Staphylococcus aureus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"staphylococcus epidermidis","label":"Staphylococcus epidermidis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"steinernema carpocapsae","label":"Steinernema carpocapsae","imageSrc":"","imageAlt":"","mod":"WormBase","modLink":"https://wormbase.org","linkVariable":""},{"value":"steinernema hermaphroditum","label":"Steinernema hermaphroditum","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"stenotrophomonas geniculata","label":"Stenotrophomonas geniculata","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"streptococcus gordonii ","label":"Streptococcus gordonii ","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"streptococcus mutans","label":"Streptococcus mutans","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":" streptococcus pneumoniae","label":"Streptococcus pneumoniae","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"s. purpuratus","label":"Strongylocentrotus purpuratus","imageSrc":"","imageAlt":"","mod":"Echinobase","modLink":"https://www.echinobase.org","linkVariable":""},{"value":"strongyloides ratti","label":"Strongyloides ratti","imageSrc":"","imageAlt":"","mod":"WormBase","modLink":"www.wormbase.org","linkVariable":""},{"value":"sulfolobus","label":"Sulfolobus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"symphoricarpos albus","label":"Symphoricarpos albus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"syncirsodes","label":"Syncirsodes","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"synechococcus elongatus","label":"Synechococcus elongatus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"syrphidae","label":"Syrphidae","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"tarantobelus jeffdanielsi","label":"Tarantobelus jeffdanielsi","imageSrc":"","imageAlt":"","mod":"WormBase","modLink":"www.wormbase.org","linkVariable":""},{"value":"taraxacum officinale","label":"Taraxacum officinale","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"tatochila theodice","label":"Tatochila theodice","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"tetrahymena","label":"Tetrahymena","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"tetramorium immigrans","label":"Tetramorium immigrans","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"tomato brown rugose fruit virus","label":"ToBRFV","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"trachemys scripta","label":"Trachemys scripta","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"tribolium castaneum","label":"Tribolium castaneum","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"trichoptera","label":"Trichoptera","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"trichuris muris","label":"Trichuris muris","imageSrc":"","imageAlt":"","mod":"WormBase","modLink":"www.wormbase.org","linkVariable":""},{"value":"trifolium repens","label":"Trifolium repens","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"trypoxylus dichotomus","label":"Trypoxylus dichotomus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"tsuga canadensis","label":"Tsuga canadensis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"ulva expansa","label":"Ulva expansa","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"universal","label":"Universal","imageSrc":"","imageAlt":"","mod":null,"modLink":null,"linkVariable":null},{"value":"vargula hilgendorfii","label":"Vargula hilgendorfii","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"vespula vulgaris","label":"Vespula vulgaris","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"virus","label":"Virus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"watasenia scintillans","label":"Watasenia scintillans","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"wolbachia pipientis","label":"Wolbachia pipientis","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"xenopus","label":"Xenopus","imageSrc":"xenopus.png","imageAlt":"Xenopus graphic by Zoe Zorn CC BY 4.0","mod":"XenBase","modLink":"https://xenbase.org","linkVariable":""},{"value":"xenorhabdus griffiniae","label":"Xenorhabdus griffiniae","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"yramea cytheris","label":"Yramea cytheris","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"zaprionus indianus","label":"Zaprionus indianus","imageSrc":"","imageAlt":"","mod":"","modLink":"","linkVariable":""},{"value":"zea mays","label":"Zea mays","imageSrc":"","imageAlt":"","mod":"MaizeGDB","modLink":"https://www.maizegdb.org","linkVariable":""},{"value":"zebrafish","label":"Zebrafish","imageSrc":"zebrafish.png","imageAlt":"Zebrafish graphic by Zoe Zorn CC BY 4.0","mod":"ZFIN","modLink":"https://zfin.org","linkVariable":""}]}},"pageContext":{"id":"13867867-dca6-4223-b4dc-74965863405e","citedBy":[],"parsedCsv":{"csvHeader":[],"csvData":[]}}}, "staticQueryHashes": ["2114697108"]}